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Abstract

APPLICATION OF MARGINAL STRUCTURAL MODELS IN
PHARMACOEPIDEMIOLOGIC STUDIES
By Shibing Yang
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2014
Directors:
Juan Lu, Ph.D., Assistant Professor
Division of Epidemiology, Department of Family Medicine and Population
Health, Virginia Commonwealth University
Kate L. Lapane, Ph.D., Professor
Department of Quantitative Health Sciences, University of Massachusetts
Medical School

Background: Inverse-probability-of-treatment-weighted estimation (IPTW) of marginal
structural models was proposed to adjust for time-varying confounders that are influenced by
prior treatment use. It is unknown whether pharmacoepidemiologic studies that applied IPTW
conformed to the recommendations proposed by methodological studies. In addition, no previous
study has compared the performance of different analytic strategies adopted in IPTW analyses.
Objectives: This project aims 1) to review the reporting practice of pharmacoepidemiologic
studies that applied IPTW, 2) to compare the validity and precision of several approaches to

constructing weight, 3) to use IPTW to estimate the effectiveness of glucosamine and
chondroitin in treating osteoarthritis.
Methods: We systematically retrieved pharmacoepidemiologic studies that were published in
2012 and applied IPTW to estimate the effect of a time-varying treatment. Under a variety of
simulated scenarios, we assessed the performance of four analytic approaches what were
commonly used in studies conducting IPTW analyses. Finally, using data from Osteoarthritis
Initiative, we applied IPTW to estimate the long-term effectiveness of glucosamine and
chondroitin on treating knee osteoarthritis.
Results: The practice of reporting use of IPTW in pharmacoepidemiologic studies was
suboptimal. The majority of reviewed studies did not report that the positivity assumption was
assessed, and several studies used unstablized weights or did not report that the stabilized
weights were used. With data simulation, we found that intention-to-treat analyses
underestimated the actual treatment effect when there was non-null treatment effect and
treatment non-adherence. This underestimation was linearly correlated with adherence levels.
As-treated analyses that took into account the complex mechanism of treatment use generated
approximately unbiased estimates without sacrificing the estimate precision when the treatment
effect was non-null. Finally, after adjustment for potential confounders with marginal structural
models, we found no clinically meaningful benefits of glucosamine/chondroitin in relieving knee
pain, stiffness and physical function or slowing joint space narrowing.
Conclusions: It may be prudent to develop best practices of reporting the use of IPTW. Studies
performing intention-to-treat analyses should report the levels of adherence after treatment
initiation, and studies performing as-treated analyses should take into the complex mechanism of
treatment use in weight construction.

Chapter 1: Background

This dissertation was motivated by the desire to quantify the effect of glucosamine and
chondroitin (Glu/Chon) on relieving knee symptoms and slowing joint structural progression
among patients knee osteoarthritis (OA). When analyzing the relation between Glu/Chon and
knee OA using data from Osteoarthritis Initiative, we were concerned that the data structure
might involve time-varying confounders that were affected by previous use of Glu/Chon. To
properly control for the confounding bias, we used inverse-probability-of-treatment-weighted
(IPTW) estimation of marginal structural models (MSM) in the analysis stage. In this
introduction chapter, we briefly discussed 1) the disease burden of OA and existing evidence
regarding the efficacy of glucosamine and chondroitin in treating OA; 2) the causal diagram
describing the relations between Glu/Chon use, study outcomes and potential confounders; and
3) application of IPTW to control for confounding and assumptions underlying IPTW estimation.
At the end of this chapter, the three specific aims of this dissertation were provided.

Glucosamine/chondroitin and knee osteoarthritis
OA is the most common form of arthritis and nearly 27 million American adults have
physician-diagnosed OA.1 OA typically affects weight-bearing joints such as hips, knees and
spine, but can also occur in non-weight-bearing joints.2 The most common OA symptoms
include joint pain and stiffness and reduced range of joint movement.2 Radiographic evidence of
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OA includes progressive narrowing of joint space, formation of subchondral sclerosis and cysts
and development of osteophytes.3 OA has detrimental effects on individuals’ physical function
and quality of life.4,5 Because of its high prevalence and the frequent disability that accompanies
disease in major joints such as the knee and hip, OA accounts for more difficulty with climbing
stairs and walking than any other disease.6
Currently, there are no curative remedies for OA and clinical guidelines recommend both
pharmacological and non-pharmacological therapies to relieve symptoms.7 Glucosamine and
chondroitin are two dietary supplements commonly used among OA patients in the United Sates.
Lapane et al. found that among patients with radiographic knee OA, 31% and 28% reported
frequent use of glucosamine and chondroitin, respectively.8 These supplements hold promise for
treating OA because both are essential components of the proteoglycan in normal cartilage and
thus may provide substrate or building blocks for the biosynthesis of proteoglycan.9, 10
Despite the biologic plausibility, evidence regarding the efficacy of glucosamine and
chondroitin in relieving OA symptoms and modifying structural progression is not established. A
recently updated Cochrane review reported a moderate clinical treatment benefit for pain
reduction in favor of glucosamine over placebo.11 However, this superiority of glucosamine was
not consistently reported by all studies included in the review. When the analysis was restricted
to studies with adequate allocation concealment or studies without connection to private
industry, no superiority of glucosamine was found.11 Regarding the efficacy in slowing joint
structural progression, two 3-year clinical trials, which were funded by one pharmaceutical
company, reported significant beneficial effect from glucosamine,12,13 whereas another two 2year publicly-funded trials found that there were no substantial benefits from glucosamine (with
or without chondroitin) in retarding joint space narrowing.14,15
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Causal diagram and time-varying confounders
We analyzed the effectiveness of Glu/Chon on treating OA using data from Osteoarthritis
Initiative (OAI), which is a multi-center observational study aimed to identify risk factors for
incidence and progression of knee OA.16 In our study, we included OAI participants with
radiographic knee OA at baseline. Annual follow-up surveys and examinations were conducted
to collect information on treatment use and changes in knee symptoms and joint structure. Our
analyses used information for the first four years.
Prior to modeling the effect of Glu/Chon on knee OA, we drew a causal diagram to help
identify potential confounders as well as methods to control for confounding. Figure 1.1 depicts
the hypothesized relationships between Glu/chon, study outcomes (including knee symptoms and
structural progression), and potential time-varying confounders. Previously measured study
outcomes and time-varying confounders may be simultaneously confounders and intermediate
variables. For instance, when studying knee pain as the outcome (i.e., Outcomet in Figure 1.1),
the pain severity measured at the previous visit (i.e., Outcomet-1) can be a potential confounder
because 1) it correlates with pain score measured at current visit (i.e., Outcomet), and 2) patients
with more severe pain are more likely to use Glu/Chon (i.e., Glu/Chont-1).8 Furthermore, if
Glu/Chon is effective in relieving pain (which is the hypothesis tested in our study), the
previously measured pain score (i.e., Outcomet-1) lies on the causal path from prior treatment use
(i.e., Glu/Chont-2) and currently measured pain (i.e., Outcomet).
If the causal structure in Figure 1.1 is true, standard regression models adjusting for
previous pain severity will produce a biased estimate of the overall treatment effect.17 Standard
regression models adjust for confounding through conditioning analyses on the potential
confounders.17 Under the causal structure in Figure 1.1, conditioning analyses on Outcomet-1 can
3

eliminate its confounding bias to the relation between Glu/Chont-1 and Outcomet. However,
conditioning analyses on Outcomet-1 also eliminates the indirect effect of Glu/Chont-2 on
Outcomet that is mediated by Outcomet-1, and thus generates a biased estimate of the overall
treatment effect of Glu/Chon on Outcomet.

Marginal structural models
To properly control for the bias by time-varying confounders that are affected by
previous treatment, Robins et al. proposed the IPTW estimation of MSM.18,19 As the name
indicates, IPTW reduces confounding through assigning a weight to each participant, which is
proportional to the inverse of conditional probability of receiving his/her observed treatment
given those time-varying confounders.19 In the resulting weighted pseudo-population, treated
participants and untreated participants are balanced over those time-varying confounders.19 Since
the analysis is not conditioned on the confounders, IPTW can properly estimate overall
treatment. In this section, we illustrated how IPTW can adjust for confounding with a simplified
example and briefly discussed the assumptions underlying this method.
A simplified example with one-time-point treatment
For illustrative purposes, we focused only on the relation between Glu/Chon and knee
pain at one time point (shown in Figure 1.2). For simplicity, we assumed that there was only one
confounder, i.e., baseline pain severity. It’s likely that patients with more severe pain (i.e., Pain0
in Figure 1.2) were more likely to use Glu/Chon (Glu/Chon0) and also more likely to report
severe pain one year later (Pain1). For simplicity, we assumed that Pain0, Glu/Chon0 and Pain1
were all binary variables, with value 1 indicating severe baseline pain, using Glu/Chon at
baseline and reporting severe pain at Year 1, respectively.
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We generated a hypothetical dataset including 100 OA participants. Distributions of the
three variables are listed in Table 1.1. The first column describes the strata formed by levels of
Pain0 and Glu/Chon0. The second column shows number of patients in each stratum. Pr(Pain1=1)
is the probability of reporting severe pain at Year 1 and Pr(Glu/Chon0|Pain0) represents the
conditional probability of receiving observed treatment (either 0 or 1) given Pain0.
In this hypothetical sample, 60% of the patients had severe pain at baseline. 66.7% and
50% took Glu/Chon among patients with severe and mild baseline pain, respectively. The
probability of having severe pain at Year 1 was 40% among patients with severe baseline pain,
and 20% among patients with mild baseline pain. Since there was no difference in the probability
of having severe pain at Year 1 between those treated and untreated with Glu/Chon within the
stratum of baseline pain severity, there was actually no treatment effect in this hypothetical
example. However, if we calculated the crude association between Glu/Chon and Pain1, crude
relative risk (RR) =

(40×0.4+20×0.2)/60

=1.11, which was apparently biased.

(20×0.4+20×0.2)/40

IPTW estimation can control for the confounding by Pain0 through assigning weights to
patients. The first step of IPTW is to construct weight. For the hypothetical sample, weight was
calculated as the inverse of conditional probability of receiving observed treatment given Pain0.
For instance, among patients with Pain0=1, the possibility of receiving treatment is 66.7%, and
possibility of not receiving treatment is 1-66.7%=33.3%. Thus the weight assigned to patients
who had severe baseline pain and received treatment was 1/0.667=1.5, and weight for those not
receiving treatment was 1/0.333=3. Accordingly, we calculated weights for patients with mild
pain at baseline. We listed the weights for each stratum of patients in the fifth column in Table
1.1.
The relative risk in the weighted population was subsequently calculated as follows:
5

Weighted RR=

(60×0.4+40×0.2)/100

(60×0.4+40×0.2)/100

=1.0, which was unbiased.

Time-varying treatment and confounders
IPTW estimation for the simplified situation depicted in Figure 1.2 can be generalized to
situations involving time-varying treatment and confounders, for example, the causal structure in
Figure 1.1. For studies with a time-varying treatment and confounders, weights are first
constructed at each assessment (time) point, which can be calculated as the unconditional
probability of receiving observed treatment divided by conditional probability of receiving
observed treatment given potential confounders.19 The final weight for each participant is the
product of his/her weights constructed at all available time points. The inclusion of the
numerator, i.e., unconditional probability of receiving observed treatment, is to improve the
precision of the final estimate.19
Identifiability assumptions
There are three conditions or assumptions, under which consistent causal effects can be
identified from non-experimental data: exchangeability, positivity and consistency.20, 21
Exchangeability assumption is also known as the assumption of no unmeasured
confounders.20,22 For longitudinal studies with time-varying exposures, exchangeability
assumption holds when there are no unmeasured confounders for treatment use at each follow-up
assessment, given the history of measured confounders and previous treatment. Exchangeability
assumption is untestable with observed data20 and is violated to some degree in almost all
epidemiologic studies. Notwithstanding, if the investigators have adequate substantive
knowledge with respect to the direction and magnitude of unmeasured confounding, sensitivity
analysis can be conducted to test the robustness of IPTW estimates to unmeasured
confounding.23
6

Positivity assumption states that each possible treatment level occurs with some positive
probability at every level of observed confounders in the study population.24,25 IPTW estimation
is more sensitive to violations of positivity assumption than standard regression models.20,25 If
the conditional probability of receiving a certain level of treatment is zero, the weight is
undefined. Furthermore, when positivity is nearly-violated, e.g., a very small proportion of the
study sample within one or more covariate strata are treated, the weights for these few
participants become very large. The disproportionate reliance of the effect estimate on the
experience of a few unusual individuals can result in substantial bias.25
The consistency condition requires that a study unambiguously define treatment and that
counterfactual outcome for each level of treatment be well-defined.20,26,27 Many nonexperimental studies violated this condition when they tried to estimate the effect of an illdefined intervention by contrasting the outcome between two groups of participants who happen
to differ with respect to some physiological measure (e.g., body mass index, low-density
lipoprotein cholesterol).26,28 Studies violating consistency assumption will have difficulty in
achieving the condition of exchangeability and may be of little help to advise public health
intervention.26,28 Therefore, some investigators propose that studies should only estimate the
causal effects of exposures that can be manipulated or be hypothetically assigned to a
person.26,27,29

Specific aims of the dissertation
When applying IPTW to estimate the effect of Glu/Chon on treating OA, we fully
realized the complexity of the process of performing IPTW analyses, as well as the importance
of various assumptions underlying this method. Therefore, besides applying IPTW to address a
real-world study question, we 1) systematically reviewed how recently published
7

pharmacoepidemiologic studies applied this method and reported findings, and 2) performed a
simulation study to assess the impact of various assumptions made in weight construction on the
validity and precision of IPTW estimates. We listed below the three specific aims of this
dissertation.

Study 1. To systematically review pharmacoepidemiologic studies published in 2012 that used
IPTW estimation of MSM to estimate the effect from a time-varying treatment

We extracted information about the type(s) of bias IPTW was used to address, how the
identifiability assumptions were assessed, how the weights were constructed and outcome
models specified, and whether substantially different results were derived from IPTW method
and standard regression models.

Study 2. To explore the impact of various assumptions made during weight construction on the
validity and precision of IPTW estimates

Using various simulated scenarios, we assessed the bias and precision of estimates derived from
four approaches to constructing weights, including IPTW assuming intention-to-treat, IPTW
assuming complex mechanism of treatment assignment, IPTW assuming simple mechanism of
treatment assignment, and IPTW assuming invariant confounders.

Study 3. To quantify the extent to which glucosamine and chondroitin relieves symptoms and
slows structural progression among persons with radiographic knee osteoarthritis
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Using IPTW, we examined the effectiveness of glucosamine and chondroitin in relieving knee
symptoms and slowing structural progression among persons with radiographic knee
osteoarthritis

9

Table 1.1. Hypothetical data corresponding to the causal diagram in Figure 1.2
Stratum

No. of
patients

*

Pr(Pain1=1) Pr(Glu/Chon0|Pain0)

Weight

†

Weighted
No. ‡

No. of events
in weighted
sample
60×40%

Pain0=1,
40
40%
40/(40+20)=0.67
1/0.67
60
Glu/chon0=1
Pain0=1,
20
40%
20/(40+20)=0.33
1/0.33
60
60×40%
Glu/chon0=0
Pain0=0,
20
20%
20/(20+20)=0.5
1/0.5
40
40×20%
Glu/chon0=1
Pain0=0,
20
20%
20/(20+20)=0.5
1/0.5
40
40×20%
Glu/chon0=0
*
Pr(Glu/Chon0|Pain0) is the probability of receiving observed treatment conditional on baseline
severity level
†
Weight=1/Pr(Glu/Chon0|Pain0)
‡
Weighted No. = Weight × No. of patients
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Glu/Chon1

Glu/Chon 2

Outcome1
& Time-varying
confounders1

Outcome2 &
Time-varying
confounders2

Year 1

Year 2

Glu/Chon 3

Glu/Chon 4

Outcome3 &
Time-varying
confounders3

Outcome4 &
Time-varying
confounders4

Year 3

Year 4

Figure 1.1. Hypothesized causal relationships between glucosamine/chondroitin treatment, study
outcomes and potential time-varying confounders
Glu/Chon denotes treatment with glucosamine/chondroitin and the subscript number denotes the
follow-up time (year) when the information was measured.
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Pain0

Glu/Chon0

Pain1

Figure 1.2. A causal diagram with one-time-point treatment
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Chapter 2: Application of marginal structural models in pharmacoepidemiologic studies: A
systematic review

13

Abstract
Objectives We systematically reviewed pharmacoepidemiologic studies published in 2012 that
used inverse-probability-of-treatment-weighted (IPTW) estimation of marginal structural models
(MSM) to estimate the effect from a time-varying treatment.
Methods Potential studies were retrieved through a citation search within Web of Science and a
keyword search within PubMed. Eligibility of retrieved studies was independently assessed by
at least two reviewers. One reviewer performed data extraction and a senior epidemiologist
confirmed the extracted information for all eligible studies.
Results Twenty pharmacoepidemiologic studies were eligible for data extraction. The majority
of reviewed studies did not report whether the positivity assumption was checked. Six studies
performed intention-to-treat analyses, but none of them reported adherence levels after treatment
initiation. Eight studies chose an as-treated analytic strategy, but only one of them reported
modeling the multiphase of treatment use. Almost all studies performing as-treated analyses
chose the most recent treatment status as the functional form of exposure in the outcome model.
Nearly half of the studies reported that the IPTW estimate was substantially different from the
estimate derived from a standard regression model.
Conclusions The use of IPTW method to control for time-varying confounding is increasing in
medical literature. However, reporting of the application of the technique is variable and
suboptimal. It may be prudent to develop best practices in reporting complex methods in
epidemiologic research.
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Introduction
A time-varying confounder is a time-varying risk factor for the study outcome which
brings about changes in the treatment use under study.30 In the presence of time-varying
confounders that are influenced by previous treatment, standard regression models may produce
biased estimate of the total treatment effect.19,31 To obtain unbiased estimate in this situation,
Robins et al. proposed the inverse probability weighted (IPTW) estimation of marginal structural
models (MSM).19,31 As the name indicates, IPTW estimation attempts to control for
confounding through assigning each participant a weight. The weight is proportional to the
inverse probability of receiving observed treatment given the time-varying confounders and
previous treatment history. The weights are then used to create a pseudo-population, in which
participants receiving treatment and those not receiving treatment are balanced over the timevarying confounders but the relationship between treatment and outcome is not changed.19
After publication of the seminal papers on MSM, methodological studies have provided
detailed insights regarding the types of bias this method handles well,17,32 the assumptions under
which consistent causal effects can be identified,23, 25, 26 and the appropriate ways of constructing
weights and building outcome models.20, 33-35 IPTW estimation has been increasingly used in
medical research, possibly due to the straightforward interpretation of the parameters derived
from MSM.35 Indeed, from 2000 to October 2009 Suarez et al. noted a 15-fold increase in the
number of studies using this approach.36
Despite the increase in studies using IPTW, the extent to which these studies conform to
the recommendations proposed by methodological studies remains unknown. The purpose of
this study was to systematically review pharmacoepidemiologic studies in which IPTW was used
to estimate the effect from a time-varying treatment. Based on information abstracted from these

15

studies, we hope to provide a broader context for scientists considering using this approach
through discussing the scenarios under which IPTW method is preferred, appropriate procedures
of conducting IPTW analyses and contents which are critical to report when using IPTW in
medical literature.

Methods
This study did not require ethics approval as no human subjects were involved.
Selection of articles
Our goal was to retrieve all pharmacoepidemiologic studies published in 2012 that used
IPTW to estimate effect from a time-varying treatment. To achieve this, we used two search
strategies. First, using the Web of Science database, we retrieved all published studies citing any
one of the seminal papers on MSM.19,20,31,37 Second, in case we missed any relevant studies
which did not cite these seminal papers, we also conducted a keyword search within PubMed.
To improve the methodological rigor of our search strategy, we worked with a research librarian
and developed the following keyword search algorithm: (marginal structural model*) OR
(“marginal structural Cox model”) OR (“inverse probability” AND ("weight" OR "weighted" OR
"weights" OR "weighting")) OR (inverse weight*). The following types of studies or
publications were excluded from the review: (1) methodological or simulation studies, (2)
studies assessing effect from a point-treatment, i.e., a treatment that was assumed invariant in the
study period; (3) non-pharmacoepidemiologic studies, i.e., studies not focusing on
pharmaceuticals, biologics, or medical devices as primary exposure; (4) letters, meeting
abstracts, review articles, and editorials.

16

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines for this review.38 After excluding duplicate records, titles and abstracts of
the remaining articles were assigned to two independent reviewers. Studies with titles and
abstracts judged relevant by at least one reviewer underwent full-text review. Any discrepancy
in eligibility judgment was resolved through discussion between the reviewers. One reviewer
(SY) performed data extraction and a senior epidemiologist (KLL) confirmed the extracted
information for all eligible studies.

Information abstraction
The following sections provide a brief description and rationale of each element of IPTW
method we chose to include in our data collection process. In particular, we extracted
information about the type(s) of bias IPTW was used to address, how the identifiability
assumptions were assessed, how the weights were constructed and outcome models specified,
and whether substantially different results were derived from IPTW method and standard
regression models.

Type of bias
As illustrated by Hernán et al.,17 compared to standard regression models, MSM has the
advantages of eliminating bias from two sources when estimating the effect from a time-varying
treatment. First, through applying inverse-probability-of-treatment weighting, IPTW can control
for the time-varying confounding while avoiding two types of bias that may arise in analyses
with standard regression models.17 The first type of bias occurs when the time-varying
confounder is simultaneously a confounder and intermediate variable. Conditioning analysis on

17

such a variable (as performed in standard regression models) will block the indirect effect from
previous treatment on study outcome that is mediated by this variable.19 Another type of bias
(called collider-stratification bias39 or selection bias17) occurs in standard regression models
when the time-varying confounder is a common effect (i.e., a collider) of previous treatment and
an unmeasured risk factor for the study outcome. Conditioning analysis on this time-varying
confounder induces a non-causal relationship between previous treatment and the unmeasured
risk factor, which introduces bias in the effect estimate of previous treatment use.17
Second, through applying inverse-probability-of-censoring weighting, MSM can control
for selection bias from informative censoring.17,32 Our review focused on the use of inverseprobability-weighting for handling selection bias from artificially censoring participants with
treatment noncompliance, e.g., discontinuing the treatment under study or switching to an
ineligible treatment.32 Bias may be introduced when this artificial censoring depends on
treatment history and also risk factors for the study outcome.40 Under certain conditions
(discussed below), IPTW can eliminate this bias by simulating a pseudo-population, in which all
participants complete the follow-up but the effect of treatment on study outcome is the same as
in the unweighted study population.41

Identifiability assumptions
There are three conditions or assumptions, under which consistent causal effects can be
identified from non-experimental data: no uncontrolled confounding, consistency and
positivity.20, 21 Consistency is the assumption that an individual’s potential (or counterfactual)
outcome under the observed treatment is precisely the observed outcome.27 Because consistency
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is often considered a reasonable assumption when estimating effects from medical treatments26,
we did not extract information on this assumption.
When there are confounders (time-invariant or time-varying) that are not measured or
measured with error, the IPTW estimates will be biased by uncontrolled confounding. We looked
for information about whether studies qualitatively discussed the susceptibility of their findings
to uncontrolled confounding and whether they performed sensitivity analyses to test the
robustness of their results when substantial uncontrolled confounding was suspected.
The positivity assumption states that each treatment level occurs with some positive
probability at every level of observed confounders in the study population.24,25 For example, this
assumption is violated when all (or almost all) patients with a specific contraindication (which is
also a risk factor for the study outcome) are untreated with the medication under study. Among
patients with the contraindication, the probability of receiving treatment will be zero (or close to
zero), and the inverse probability will be inestimable (or a very large number). The
disproportionate reliance on the experience of a few unusual individuals (i.e., treated patients
with the contraindication) in the weighted population can result in imprecise and biased effect
estimate.25 Thus, we extracted information about (1) whether studies reported that the positivity
assumption was checked, (2) how the positivity assumption was evaluated, and (3) how
violations of the assumption were handled (if detected).

Constructing weights
The validity of IPTW estimates depends on correct construction of weights.19, 21 There
are two types of weights--unstabilized and stabilized. The unstablized weight is calculated as the
inverse of conditional probability of receiving observed treatment given the history of time-
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varying confounders and previous treatment history (called weight denominator).19 The
stabilized weight can be calculated as the product of the conditional probability of receiving
observed treatment given baseline confounders and previous treatment history (called weight
numerator) and the unstabilized weight. The stabilized weight is generally recommended
because it can yield estimates with greater precision compared to the unstabilized weight.19 The
conditional probability of receiving observed treatment (for weight numerator and denominator)
is often estimated with a regression model (i.e., treatment model).
When non-compliance after treatment initiation is low, an observational intention-to-treat
(ITT) analysis with IPTW has been recommended.19, 20, 37 Specifically, this strategy assumes that
once a participant initiates treatment, the participant will remain on treatment for the remainder
of the study period. This assumption simplifies the process of estimating the probability of
receiving observed treatment history, because only one model is needed to estimate the
probability of treatment onset.42 In addition to ITT analyses, analogous to data analysis of a
clinical trial, a non-experimental study can perform per-protocol and as-treated analyses using
IPTW.40 In a per-protocol analysis, a comparison is made only among those who adhere to the
treatment under study and patients are censored when they deviate from the initial treatment. In
an as-treated analysis, individuals are classified according to the treatment they receive during
the follow-up rather than the treatment they initiate, and patients who stop or switch the
treatment are also included in the analysis.
We extracted information about the analytic strategy each study adopted, and how they
specified the treatment models for the weight numerator and denominator. For studies not
assuming ITT, we assessed whether or not the authors modeled the multiphase of treatment use
(e.g., treatment initiation, continuation, etc.) and how this was done.

20

Outcome model building
After weights are constructed, a weighted regression model (i.e., outcome model) is
typically fit to estimate the effect of treatment on the outcome.20 All the variables included in the
treatment model for the weight numerator should also be included in the outcome model,
because they are not balanced between treated and untreated participants in the weighted
population and thus can still bias the estimate.20 Substantive expertise should drive the selection
of the functional form of exposure in the outcome model.42,43 For instance, under the assumption
of a linear relationship between treatment duration and study outcome, studies can specify
exposure as the total duration of previous treatment use, and the estimate then quantifies the
effect from each additional time unit (e.g., one month) of treatment;19,40 studies performing ITT
analyses can also specify exposure with an indicator for treatment initiation (yes or no) to
estimate the average effect of initiating treatment in the follow-up period.40 In this review, we
assessed what covariates were included in the outcome model and how they specified the
functional form of exposure.

Discrepancy between IPTW estimates and standard regression estimates
The review by Suarez et al. reported that more than half of the studies using IPTW
method yielded an estimate substantially different from that produced by standard regression
models.36 However, the review did not provide information about how studies discussed reasons
for such discrepancy. In this review, we assessed whether studies found a substantial difference
in estimates between the two methods and further extracted information about how studies
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explained the discrepancy when it was noted. We considered a difference “substantial” if the
difference was more than 20% of the IPTW estimate.36

Results
Figure 2.1 depicts the process of identifying studies eligible for the review. We retrieved
164 and 137 studies from citation search in Web of Science and keyword search in PubMed,
respectively. After excluding duplicate studies (n=66), methodological or simulation studies
(n=92), review studies (n=9), studies not focusing on a health-related outcome (n=12) or not
using IPTW (n=7), studies assessing effect from a point-treatment (n=66), and nonpharmacoepidemiologic studies (n=26), we had 23 pharmacoepidemiologic studies which
applied IPTW to estimate effect from a time-varying treatment. Among these 23 studies, three
used IPTW to evaluate effects from dynamic treatment regimens.44-46 Considering that weight
construction for estimating effects from dynamic regimens is different from that for static
regimens,47 we excluded these studies from the review. Data extraction was performed on the
remaining 20 studies.48-67
Table 2.1 shows a brief description of the study design, primary exposure and outcome
and potential time-varying confounders. Three studies compared treatments that were
randomized to participants.48,58,64 However, they performed analyses as if data were collected
from a non-experimental design, so we included them in the review. Half of the 20 studies
assessed benefits or risks from antiretroviral therapy among HIV-infected patients51,53,56,57,59,63,67
or risk of HIV transmission from contraceptive use;54,60,62 five studies focused on treatment or
prevention of cardiovascular diseases;48-50,52,64 two studies assessed treatments for chronic kidney
disease;55,61 and there was one study assessing the effect of treatment for a protein metabolism
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disorder,65 schizophrenia,66 and breast cancer,58 respectively. The primary outcome of most
studies was mortality (n=7) or first occurrence of a pre-specified event (n=12), and one study
considered a repeated-measure outcome.67 With the exception of two studies,52,58 all reviewed
studies provided information on the time-varying confounders.
In Table 2.2, the type of bias IPTW addressed and details regarding the assumptions of
positivity and no uncontrolled confounding are described for each study. Eleven studies used
IPTW owing to concerns that standard regression models might eliminate indirect effects
mediated by time-varying confounders, five studies used IPTW to deal with bias from the
artificial censoring of noncompliance, and five studies did not provide further details other than
stating that IPTW was used because of “concerns of time-varying confounding”. The majority
of studies did not report whether the positivity assumption was checked. Four studies truncated
weights and one study trimmed weights to alleviate the impact of potential positivity violation.
Most studies discussed qualitatively the susceptibility of their findings to uncontrolled
confounding, but none reported performing formal sensitivity analyses to assess robustness of
the results to uncontrolled confounding.
Table 2.3 includes information on the construction of weights and specification of
outcome models. Six studies performed ITT analyses, three performed per-protocol analyses and
eight performed as-treated analyses. None of the studies assuming ITT reported adherence levels
after treatment initiation. The three “per-protocol” studies censored patients when they
discontinued the treatment under study, and estimated the probability of treatment continuation
(i.e., being uncensored) separately from treatment initiation. One of the eight “as-treated”
studies modeled current treatment use stratified by previous treatment status.
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One study did not use stabilized weights, four did not report whether stabilized weights
were used, and eight reported using stabilized weights but did not describe how it was done. The
remaining studies reported stabilizing weights with unconditional probability of receiving
observed treatment, or conditional probability given baseline covariates and previous treatment
or given baseline covariates only. For the weight denominator, twelve studies estimated the
conditional probability given baseline covariates, time-varying confounders and previous
treatment, three did this given baseline covariates and time-varying confounders and two
adjusted for baseline covariates plus “follow-up period” or baseline covariates only. Four studies
selected variables in the treatment model for weight denominator based on a statistical criterion.
Two studies included covariates with statistically significant associations with the study outcome
and subsequent treatment use. One study included factors significantly associated with the study
outcome only. One study used a stepwise procedure to select the treatment model which
maximized Akaike information criterion.
Regarding the functional form of exposure in the outcome model, studies performing ITT
and per-protocol analyses included an indicator of treatment initiation and the initial treatment
status, respectively. Almost all studies performing as-treated analyses included only the most
recent treatment status in the outcome model.
Table 2.4 shows crude estimates, and estimates from IPTW and standard regression
models for the associations between primary study exposure and outcome listed in Table 2.1.
The last column contains information about whether the IPTW estimate was substantially
different from the standard regression estimate for any association assessed in the study, as well
as how the study explained any noted discrepancies. Fourteen studies reported results from both
methods and a substantial difference was found in six studies. Among studies reporting a
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substantial difference, three did not discuss reasons for the discrepancy, two considered IPTW
method correctly estimated the indirect effects from previous treatments, and one considered
IPTW method controlled for “confounding by indication”.
We summarized the review results of the 20 studies in Table 2.5.

Discussion
Our review supports the notion that studies using IPTW to deal with time-varying
confounding continue to diffuse in the medical literature. In 2012, 49 studies used IPTW to
estimate the effect from a time-varying exposure on a health-related outcome. After reviewing
20 pharmacoepidemiologic studies, we found that the majority lacked sufficient details to
evaluate the appropriateness of the application of the method. Most studies did not report that
the positivity assumption was checked, and more than half did not report the type of weights
(stabilized or unstabilized) applied or how the weights were stabilized. Furthermore, we found
that more studies performed as-treated analyses than ITT analyses, but few of these studies
considered the multiphase of treatment use in the process of weight construction and almost all
chose the most recent treatment status as the functional form of exposure in the outcome model.
Assessment of positivity assumption. Surprisingly, the majority of reviewed studies did
not report whether they checked the positivity assumption. The IPTW method is more sensitive
to positivity violations than standard regression models.20,25 Studies using simulated68 and
empirical69 data have demonstrated that positivity violations could result in substantial bias and
imprecision in IPTW estimates. Estimated stabilized weights with the mean far from one or with
very extreme values can be indicative of non-positivity.20 Thus, a thorough examination of the
weight distribution is essential for checking the positivity assumption.20,36 However, a “well-
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behaved” weight distribution (i.e., with mean close to one and moderate range) is not sufficient
to ensure the absence of positivity violations.25,70 Thus, Cole et al. recommended assessing the
robustness of IPTW estimates with weights truncated at certain percentiles (e.g., 99th, 95th and
90th) as sensitivity analyses.20
Assessment of uncontrolled confounding. Although it was difficult to judge the adequacy
of control for confounding in the reviewed studies without knowledge in the specific datasets and
subject areas, we did find that some studies reported adjusting for “follow-up period” as the only
time-varying confounder or adjusting for only baseline covariates. If time-varying disease risk
factors that cause changes in treatment use are not correctly measured and appropriately adjusted
for, the IPTW estimates will be biased. When substantial uncontrolled confounding is suspected,
sensitivity analyses have been recommended to assess the robustness of the IPTW estimates.23,71
To perform such sensitivity analyses, investigators need to specify a plausible function form
which quantifies the direction and magnitude of uncontrolled confounding.23,71
ITT analyses. When non-adherence after treatment initiation is minimal, an ITT analysis
may be preferred to as-treated analysis in terms of simplifying the weight construction and
controlling for confounding.42,44,47 The ITT assumption simplifies the process of constructing
weights, in that the treatment models only need to estimate the probability of treatment initiation.
More importantly, for studies performing ITT analyses, the assumption of no uncontrolled
confounding is satisfied as long as confounders for treatment onset are correctly measured and
specified in the treatment model for weight denominator. This assumption may be viable for
many pharmacoepidemiologic studies using healthcare database, because “information used by
physicians to make a decision to initiate treatment is often captured in the database”.44 However,
the ITT estimate merely measures the effect of treatment initiation instead of effect from actual
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treatment.41 High levels of non-adherence after treatment initiation may drive the ITT estimate
away from the true treatment effect.42,72 For this reason, studies performing ITT analyses should
report adherence measures for each treatment arm so that findings can be interpreted under
appropriate consideration of the observed adherence patterns.73
As-treated analyses. Instead of estimating the effect of treatment initiation, we found that
more studies performed as-treated analyses. Validity of “as-treated” estimates relies on the
extent to which the study correctly models the relationships between confounders and the
multiphase of treatment use.42 Because it is very likely that the influence of time-varying
confounders on initiating a treatment is different from their impact on continuing or resuming the
treatment, separate models for different treatment regimens are often needed for adequate control
for confounding. However, when information on time-varying confounders that predict
treatment changes after initiation is not well-recorded in the data sources or when the number of
participants following each specific regimen is small, a correct estimation of the multiphase of
treatment use will be difficult, if not impossible.42,44,47 In sum, when choosing between an ITT
and an as-treated analytic strategy, investigators need to take into account adherence levels after
treatment initiation and availability of information on the time-varying confounders that predict
treatment changes during the study period.
Weight construction. Stabilized weights can generate estimates with greater precision
than unstabilized weights and thus are recommended in data analyses.37 However, we still found
that four studies did not report whether they used stabilized weights and one study used
unstablized weights. It’s unknown to us why unstabilized weights were chosen. Regarding
variable selection for treatment model in the weight denominator, we found that most studies
chose covariates based on substantive knowledge, while four studies used some statistical
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criterion to select covariates significantly associated with treatment use and/or study outcome. A
simulation study by Lefebvre et al. found that the performance of IPTW method could be
improved when the confounders and risk factors of outcome were included in the treatment
model, whereas including pure predictors of treatment use (i.e., not confounders) led to biased
and highly variable estimates, particularly in the context of small samples.33 These findings are
consistent with the recommendation for variable selection for building propensity scores.74
Therefore, an advisable strategy in building treatment model for weight denominator may be to
include variables considered to be direct risk factors for the outcome.
Functional form of exposure in outcome models. Almost all studies performing astreated analyses included only the most recent treatment status in the outcome model. Most of
these studies chose IPTW method instead of standard regression models owing to the concerns
that standard models would eliminate the indirect effect from previous treatments mediated by
the time-varying confounders. This may imply that these studies were interested in estimating
the effects from both recent and previous treatments. However, when treatment use is
intermittent, including only the most recent exposure status in the outcome model will not
correctly capture the effect from previous treatments. Furthermore, when the weights are
stabilized with previous treatment history but only the indicator of most recent treatment use is
included in the outcome model, the estimate may also be a biased one for the recent treatment
effect, because the status of previous treatment is not balanced between recently treated and untreated patients and thus may bias the estimate.75 Finally, if only the most recent treatment effect
is biologically plausible and is the focus of the study, standard regression models adjusting for
time-varying confounders and previous treatment history can also produce unbiased estimate,37,70
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even though there is disagreement regarding the difference in precision between estimates
derived from IPTW and standard regression models.76,77
Discrepancy in estimates from IPTW and standard regression models. Similar to the
previous review,36 we found nearly half of the studies, which provided estimates from both
methods, reported that IPTW estimates were substantially different from the standard regression
estimates adjusted for time-varying confounders. Unfortunately, half of the studies reporting a
substantial difference did not discuss reasons for the discrepancy. As mentioned in the section
Type of bias, the discrepancy can be attributed to the correct estimation of total treatment effect
or avoidance of collider-stratification bias by the IPTW method, especially if the direction of
discrepancy is consistent with the hypothesized relationships between exposure, outcome and
time-varying confounders. In addition, the difference can be due to control for selection bias
from informative censoring if censoring weights are incorporated in IPTW analyses.
Non-uniform treatment effects. Several studies also noticed that substantial discrepancy
in estimates could arise in the presence of covariates (or a summary of covariates like propensity
score) which strongly predict treatment use and are also strong effect modifiers.69,78,79
Compared to the standard regression models, the IPTW method gives much more weights to the
covariate strata within which treatment status is almost completely determined by the
covariates.80,81 If the effect sizes in these strata differ dramatically from other strata, the IPTW
estimates will be substantially different from the standard regression estimates.81 The nonuniform treatment effects across the covariates (or the propensity score) can be due to violation
of positivity,69 unmeasured confounding78 or true effect-measure modification. When
unmeasured confounding or positivity violation is the cause of non-uniformity, the IPTW
estimate will be biased and weight truncation or propensity score trimming should be applied to
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ameliorate the impact.69,78 In summary, when substantially different estimates are derived from
IPTW and standard regression models, investigators should take into account these alternative
explanations before being assured that IPTW method generates unbiased estimates.
Our review has some limitations. First, we included only pharmacoepidemiologic studies
published in 2012. The findings may not be representative of all publications using IPTW to
deal with time-varying confounding. Second, the reporting practices of published studies may be
influenced by journals’ requirements. Authors are reporting their findings given strict word
limitations and as such may have limited space to provide details on these facets of the
application of the method. Nevertheless, with complex methods such as IPTW, such reporting is
necessary to evaluate the extent to which the method has been appropriately applied.
In summary, the use of IPTW estimation is increasing in the medical literature. Given
the variable and suboptimal reporting of the application of the technique, it may be prudent to
develop best practices in reporting complex methods in epidemiologic research and for journal
editors to consider adopting such reporting guidelines.
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Table 2.1. General description of pharmacoepidemiologic studies published in 2012 and eligible
for the systematic review.
Reference
Cook et al.48
Desai et al. 49

Study
design
Randomized
controlled
trial
Cohort

Gerhard et al. 50

Cohort

Gsponer et al. 51

Cohort

Haukka et al. 52

Cohort

HCV working
group of
COHERE 53

Cohort

Heffron et al. 54

Cohort

Hernández et al.

Cohort

55

HIV-CAUSAL
Collaboration 56
HIV-CAUSAL
Collaboration 57
Jin et al. 58

Kalayjian et al.
59

McCoy et al. 60

Cohort
Cohort

Exposure &

Outcome &

Aspirin vs. notreatment

CVD or CVDrelated
mortality
Mortality

Candesartan vs.
losartan
Aggressive vs.
conventional
antihypertensive
therapies
Switching to secondline ART vs. firstline ART
Statins vs. notreatment
Hepatitis C treatment
vs. no-treatment

CVD or
mortality

Blood pressure

Mortality

CD4 cell count

Mortality

Not reported †

Mortality

CD4 cell count, HIV
RNA level, platelet
counts, alanine
aminotransferase
levels
Pregnancy,
unprotected sex

Hormonal
contraceptive vs. notreatment
ACEI/ARB vs. notreatment

HIV infection

Nevirapine vs.
efavirenz
ART vs. notreatment
Letrozole vs. notreatment

Mortality

Randomized
controlled
trial
Cohort
Tenofovir+ ritonavirboosted protease
inhibitor vs.
efavirenz/nevaripine
Cohort
Injectable hormonal
contraceptive vs. notreatment

31

Time-varying
confounders
CVD risk factors,
intermediate CVD
events
Hospitalization

Graft failure

Tuberculosis
Cancer
recurrence

Smoking,
concurrent
medication use
CD4 cell count, HIV
RNA level, AIDS
CD4 cell count, HIV
RNA level, AIDS
Not reported *

Chronic
kidney disease

CD4 cell count, viral
load

HIV infection

Sexual behavioral
risk, condom use,
sexually
transmitted
infections

Miller et al. 61

Cohort

Low dose vs. high
dose paricalcital

Mortality

Morrison et al.

Cohort

Oral contraceptive
vs. non-hormonal use

HIV infection

Scherzer et al. 63

Cohort

Tenofovir vs. notreatment

Proteinuria

Shinozaki et al.

Atorvastatin vs. notreatment

CVD

Terrier et al. 65

Randomized
controlled
trial
Cohort

Tiihonen et al.

Cohort

Corticosteroid +
rituximab vs.
corticosteroid alone
Benzodiazepine vs.
no-treatment

Renal and
immunological
response
Mortality

Tenofovir +
ritonavir-boosted
lopinavir vs.
renofovir+efavirenz

eGFR

62

64

66

Young et al. 67

Cohort

Parathyroid
hormone,
phosphorus, calcium
Sexual behavioral
risk, condom use,
genital symptoms
CD4 cell count, viral
load, lipids, diabetes,
hypertension
Lipid profiles,
HbA1c, blood
pressure, BMI
Vasculitis
manifestations
Concurrent
medication use

HIV-infection,
diabetes,
hypertension,
hepatitis B or C
infection, eGFR,
CD4 cell count,
virological failure
ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers; ART:
antiretroviral therapy; CVD: cardiovascular diseases; eGFR, estimated glomerular filtration rate.
&
Only the primary study exposure and outcome were reported in this table. “No-treatment”
means not using the treatment under study.
†
This study did not describe any specific substantial time-varying confounders for which
adjustment was needed.
*
This study used inverse probability of censoring weighting to deal with treatment crossover.
Probability of treatment crossover was estimated based on baseline characteristics. Time-varying
confounders were not mentioned.
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Table 2.2 Type of potential bias and examination of identifiability assumptions
Reference
Cook et al.48

Type of potential
bias addressed
Bias from
blocking
mediated effect

Desai et al. 49

Bias from
blocking
mediated effect;
Selection bias
owing to artificial
censoring
50
Gerhard et al.
Bias from
blocking
mediated effect
Gsponer et al. 51
Bias from
blocking
mediated effect
Haukka et al. 52
No details
provided†
HCV working
Bias from
group of COHERE
blocking
53
mediated effect
Heffron et al. 54
No details
provided†
Hernández et al. 55

HIV-CAUSAL
Collaboration 56
HIV-CAUSAL
Collaboration 57
Jin et al. 58
Kalayjian et al. 59
McCoy et al. 60

Bias from
blocking
mediated effect
Selection bias
owing to artificial
censoring
Bias from
blocking
mediated effect
Selection bias
owing to artificial
censoring
Selection bias
owing to artificial
censoring
Bias from

Positivity assessed

Weight truncated
or trimmed

Mean: 1.01
Weight truncation
Median
at 0.01th and
(Inter Quartile
99.99th
Range):
percentiles
1.00 (0.97-1.01)
Mean
Not reported
(Standard Deviation):
1.00 (0.06)

Uncontrolled
confounding
discussed
Yes

Yes

Not reported

Not reported

Yes

Not reported

Not reported

Yes

Not reported

Not reported

Yes

Not reported

Not reported

Yes

Mean (range):
1.07 (0.82-1.34)

Weight truncation
at 1st and 99th
percentiles
Not reported

Yes

Not reported

Weight truncation
at 99th percentile

Yes

Mean: 1.04

Weight truncation
at 10

Yes

Not reported

Not reported

No

Not reported

Not reported

Yes

Not reported

Not reported

Yes

Not reported
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Yes

blocking
mediated effect
Miller et al. 61
Bias from
Not reported
Weight Trimming
Yes
blocking
at 10
mediated effect
Morrison et al. 62
No details
Not reported
Not reported
Yes
provided†
Scherzer et al. 63
Bias from
Not reported
Not reported
Yes
blocking
mediated effect
Shinozaki et al. 64
Bias from
Not reported
Not reported
Yes
blocking
mediated effect
Terrier et al. 65
No details
Not reported
Not reported
No
provided†
Tiihonen et al. 66
No details
Not reported
Not reported
Yes
provided†
Young et al. 67
Selection bias
Not reported
Not reported
No
owing to artificial
censoring
†
If studies reported “using IPTW to control for time-varying confounding” without further
specification of relationships between treatment, time-varying confounders and outcomes.

34

Table 2.3. Specification of treatment models and outcome models
Reference

Analytic strategy*
Adherence level

Cook et al.48

As-treated
73% stayed on
initial treatment

Desai et al. 49

As-treated
Not reported

Multiphase of
treatment use
modeled
Yes.
Current use
modeled by
status of
previous use
No

Variables in
weight numerator
/ Stabilized
Baseline
confounders,
previous
treatment

Variables in weight
denominator/
Covariates selection
Baseline confounders,
time-varying
confounders,
previous treatment

Covariates
in outcome
model
Baseline
confounders

Functional
form of
exposure
Most recent
exposure

Baseline confounders,
time-varying
confounders,
previous treatment
Baseline confounders,
time-varying
confounders,
previous treatment
Baseline confounders,
time-varying
confounders,
previous treatment /
Stepwise selection
based on Akaike
information criterion
Baseline confounders,
follow-up time

Baseline
confounders

Not reported

Not reported

Indicator of
treatment
initiation

Baseline
confounders

Indicator of
treatment
“initiation”†;
Time to
treatment
“initiation”†

Not reported

Most recent
exposure

Not reported

Indicator of
treatment
initiation

Gerhard et al. 50

Intention to treat
Not reported

Not applicable

Baseline
confounders,
previous
treatment
Not reported /Yes

Gsponer et al. 51

Intention to treat
Not reported

Not applicable

Not reported /Yes

Haukka et al. 52

As-treated
Treatment use
covered 73% of
study period
Intention to treat
Not reported

No

Baseline
confounders

Not applicable

Not reported /Yes

HCV working
group of
COHERE 53
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Baseline confounders,
time-varying
confounders,
previous treatment

Heffron et al. 54

As-treated
52.0% stayed on
treatment

No

Not reported /Yes

Hernández et al.

As-treated
>85% stayed on
treatment

No

Not reported /
Not reported

HIV-CAUSAL
Collaboration 56

Intention to treat
Not reported

Not applicable

None/No

HIV-CAUSAL
Collaboration 57

Intention to treat
Not reported

Not applicable

Not reported /
Yes

Jin et al. 58

Per-protocol
31% stayed on
initial treatment

Not reported /
Not reported

Baseline confounders, Not reported
previous Treatment /
Variables significantly
associated with
outcome and treatment
crossover

Kalayjian et al.

Per-protocol
64% stayed on
initial treatment

Yes.
Treatment
initiation and
“treatment
crossover” was
considered
separately
Yes.
Treatment
initiation and
discontinuation
modeled
separately

Not reported /
Not reported

Baseline confounders,
time-varying
confounders,
previous treatment

55

59
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Baseline confounders,
time-varying
confounders

Baseline
confounders

Most recent
exposure

Baseline confounders, Not reported
time-varying
confounders /
Variables significantly
associated with
outcome
Baseline confounders,
Baseline
time-varying
confounders
confounders,
previous treatment
Baseline confounders,
Baseline
time-varying
confounders
confounders,
previous treatment

Most recent
exposure?

Not reported

Initial
treatment

Indicator of
treatment
initiation;
Cumulative
exposure
Initial
treatment

Initial
treatment

McCoy et al. 60

As-treated
51.6% stayed on
treatment

No

Miller et al. 61

As-treated
Not reported

No

Morrison et al. 62

As-treated
64.4% stayed on
treatment

No

Not reported /
Yes

Scherzer et al. 63

Not reported

Not reported

Not reported /
Yes

Shinozaki et al.

Intention to treat
Not reported

Not applicable

Baseline
confounders

Terrier et al. 65

Not reported

Not reported

Tiihonen et al. 66

Not reported

Not reported

Young et al. 67

Per-protocol
Not reported

Yes.
Treatment
initiation and

Baseline
confounders
Not reported/
Not reported
Unconditional
probability of
receiving

64

Unconditional
probability of
receiving
observed
treatment
Not reported /
Yes
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Baseline confounders,
time-varying
confounders,
previous treatment

Not reported

Most recent
exposure

Baseline confounders, Not reported
time-varying
confounders,
previous treatment
Baseline confounders,
Baseline
time-varying
confounders
confounders /
Covariates
significantly
associated with
outcome and treatment
use and also predicted
by past treatment use
Not reported
Baseline
confounders

Most recent
exposure?

Baseline confounders,
time-varying
confounders,
previous treatment
Not reported

Baseline
confounders

Not reported

Not reported

Not reported

Baseline confounders,
time-varying
confounders,

None

Most recent
exposure

Cumulative
exposure;
“Ever
exposure”
Indicator of
treatment
initiation
Most recent
exposure
Not reported
Initial
treatment

discontinuation
observed
previous treatment
modeled
treatment
separately
*
If the study stated that “modeling the probability of receiving observed treatment at each time visit”, we assumed that the study was
not making the assumption of intention-to-treat.
†
“Initiation” refers to switching to the second-line therapy after treatment failure with first-line therapy.
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Table 2.4. Primary exposure-outcome association† and discrepancy in IPTW estimates and
standard regression estimates
Reference

Crude Hazard Ratio
(95% Confidence
Interval)

IPTW Hazard
Ratio* (95%
Confidence
Interval)

Cook et al.48

1.00 (0.89-1.14)

0.93 (0.81-1.07)

Standard
regression
Hazard Ratio*
(95% Confidence
Interval)
0.96 (0.84-1.09)

Desai et al. 49

Adjusted for
baseline covariates:
0.89 (0.7-1.06)
Adjusted for
baseline covariates:
0.96 (0.87-1.07)
0.52 (0.20-1.35)

0.79 (0.42-1.50)

Not reported

Yes
Correction of
blocked
mediated effect
Not applicable

0.81 (0.71-0.92)

Not reported

Not applicable

0.25 (0.09-0.72)

Not reported

Not applicable

NR

0.42 (0.37-0.47)

0.39 (0.37-0.40)

No

0.50 (0.35, 0.71)

0.72 (0.43-1.21)

Not reported

Not applicable

1.73 (0.95-3.15)
0.77 (0.49-1.21)

1.84 (0.98-3.47)
0.82 (0.52-1.32)

1.98 (1.06-3.68)
0.80 (0.51-1.26)

No
No

1.46 (1.21-1.76)

1.59 (1.27-1.98)

1.38 (1.13-1.68)

Adjusted for
baseline covariates:
0.81 (0.67-0.97)
0.68 (0.56-0.83)

0.56 (0.44-0.72)

1.03 (0.86-1.24)

Yes
Not reported
Yes
Not reported

0.52 (0.45-0.61)

0.58 (0.47-0.72)

Not reported

3.35 (1.40-8.02)

1.34 (0.75-2.40)

McCoy et al. 60
Miller et al. 61

1.32 (1.00-1.74)
Not reported

1.34 (0.75-2.37)
1.26 (1.19-1.35)

1.37 (1.01-1.85)
1.07 (1.01-1.14)

Morrison et al. 62

0.89 (0.55-1.44)

0.84 (0.51-1.39)

0.88 (0.49-1.30)

Not reported as
such
Yes
Not reported
No
Yes
Confounding by
indication
No

Scherzer et al. 63

Adjusted for
baseline covariates:
1.30 (1.22-1.37)

1.24 (1.17-1.32)

1.34 (1.25-1.45)

No

Gerhard et al. 50
Gsponer et al. 51
Haukka et al.

52

HCV working
group of
COHERE 53
Heffron et al. 54
Hernández et al.

Discrepancy
found
Reason
discussed

55

HIV-CAUSAL
Collaboration 56
HIV-CAUSAL
Collaboration 57
Jin et al. 58
Kalayjian et al. 59

39

Shinozaki et al. 64

Terrier et al. 65
Tiihonen et al. 66
Young et al.

67

Adjusted for
baseline covariates:
0.65 (0.30-1.40)

0.48 (0.19-1.16)

0.75 (0.34-1.63)

Not reported

3.7 (1.3-10.6)

Not reported

Yes
Correction of
blocked
mediated effect
Not applicable

1.61 (1.06-2.45)

1.80 (1.02-3.20)

1.91 (1.13-3.22)

No

Not reported

Not applicable

Beta coefficient of
exposure term from
linear model:
-4.6 (-8.6 to -0.5)

Beta coefficient
of exposure
term from linear
model:
-2.6 (-7.3 to 2.2)
†
Primary exposure and outcome are listed in Table 2.1.
*
Adjusted for potential time-varying confounders.
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Table 2.5. A summary of review results of the 20 pharmacoepidemiologic studies applying
IPTW method in 2012
Elements of IPTW method

No. of studies
(percent#)

Types of bias IPTW was used to address
Blocking mediated effects by time-varying confounders
11 (55)
Collider-stratification bias
0
Selection bias due to artificial censoring
5 (25)
Assessment of identifiability assumptions
Discussed qualitatively uncontrolled confounding
17 (85)
Performed sensitivity analyses of uncontrolled confounding
0
Reported the weight distribution
4 (20)
Reported truncating or trimming extreme weights
5 (25)
Analytic strategy
Intention-to-treat analysis
6 (30)
Per-protocol analysis
3 (15)
As-treated analysis
8 (40)
Weight construction
15 (75)
Reported use of stabilized weights
7 (47†)
Described how weights were stabilized
Described covariates in the treatment model for weight
17 (85)
denominator
Modeled the multiphase of treatment use
1 (12.5&)
Functional form of exposure in outcome models
Indicator of treatment initiation or initial treatment use
9 (100^)
Most recent treatment use
7 (100*)
Discrepancy in estimates between IPTW and standard regression
Discussed reasons for the substantial discrepancy
3 (50§)
#
The denominator is 20 unless indicated otherwise.
†
The denominator is 15 studies which reported using stabilized weights.
&
The denominator is 8 studies performing as-treated analyses.
^ The denominator is 9 studies performing intention-to-treat or per-protocol analyses. One study
performing intention-to-treat analyses also specified cumulative exposure as an alternative.
*
The denominator is 7 studies performing as-treated analyses which provided information on the
functional form of exposure.
§
The denominator is 6 studies reporting substantial difference.
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Figure 2.1. Identification of pharmacoepidemiolgoical studies using IPTW to deal with timevarying confounding in 2012
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Chapter 3: The choice of analytic strategies in inverse-probability-of-treatment-weighted
analysis: A simulation study
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Abstract
Objectives To explore the impact of several assumptions made during weight construction on
the validity and precision of estimates derived from inverse-probability-of-treatment-weighted
analysis (IPTW). In particular, we compared the performance of 1) IPTW assuming intention-totreat; 2) IPTW assuming complex mechanism of treatment assignment; 3) IPTW assuming
simple mechanism of treatment assignment; and 4) IPTW assuming invariant confounders.
Methods We simulated data assuming a non-experimental design and aimed to quantify the
effect of statin on lowering low-density lipoprotein cholesterol (LDL-C). Overall, 324 scenarios
were simulated with parameter values varied on effect size, sample size, adherence level,
probability of treatment initiation, and associations between LDL and treatment initiation and
continuation. Effect estimates were derived from four IPTW approaches, and bias and precision
of the estimates were evaluated.
Results IPTW estimates assuming intention-to-treat were biased towards to the null when there
was non-null treatment effect and non-adherence after treatment initiation. For each one percent
decrease in treatment adherence experienced by the sample, the bias in the average treatment
effect increased by one percent. Compared to analyses assuming a simple mechanism of
treatment assignment or invariant confounders, IPTW analyses that took into account the
complex mechanism of treatment assignment generated unbiased estimates without sacrificing
precision.
Conclusions Bias in IPTW estimate that assumes an intention-to-treat depends on the level of
adherence after treatment initiation. Studies performing ITT analyses should report adherence
measures after treatment initiation so that findings can be interpreted under appropriate
consideration of the observed adherence patterns. Studies attempting to estimate the actual effect
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of a time-varying treatment need to take into account the complex mechanism of treatment
assignment in weight construction.
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Introduction
Inverse probability of treatment weighted (IPTW) estimation of marginal structural
models (MSM) has been increasingly used to adjust for time-varying confounding in
pharmacoepidemiologic studies.82 Unlike conventional methods, IPTW reduces confounding
through assigning a weight to each participant, which is proportional to the inverse of conditional
probability of receiving the observed treatment given confounders.17,19 In the presence of timevarying confounders that are influenced by previous treatment, IPTW can adjust for the
confounding without blocking the mediated effect or introducing selection bias.17,19
The validity of IPTW method relies on the correct estimation of the conditional
probability of receiving observed treatment.19, 21 Many studies applying IPTW have made an
observational intent-to-treat assumption.82 Specifically, this means that once treatment is
initiated, patients are assumed to stay on that treatment for the remaining study period.42 The
advantages to invoking this assumption are that doing so simplifies the weight construction
process and the assumption of no uncontrolled confounding.42,44,82 However, for almost all
studies assessing effect of a medication on a health-related outcome, the intention-to-treat
assumption is violated to some degree.83 In routine clinical practice in the United States, around
one third to one half of the patients do not take medications as prescribed by their doctors.84
When non-adherence is substantial, ITT analyses may estimate the effect of initiating a
treatment, rather than the actual treatment effect.85
Our previous review reported that many studies using IPTW chose an as-treated analytic
strategy,82 i.e., they categorized patients according to the treatment actually received by patients
during the study period.40,85 Different from ITT analyses, as-treated analyses attempted to
estimate the effect from actual treatment.85 To correctly estimate the actual effect from a time-
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varying treatment, investigators need to take into account the complex mechanism of treatment
assignment in the process of weight construction.42 For instance, several applications of IPTW
have demonstrated that the relationships of confounders to initiating the treatment under study
were different from continuing the treatment.48,86 However, our review found that few studies
performing as-treated analyses actually considered the complex mechanism of treatment
assignment during weight construction.82
To our knowledge, no previous study has evaluated the impact of adopting different
analytic strategies on the validity and precision of the IPTW estimates. The objectives of this
study were to (1) compare the performance of several commonly-used analytic approaches to
constructing weights and (2) explore the impact of several study characteristics, e.g., adherence
level, prevalence of treatment use and magnitude of confounding, on the performance of
different analytic approaches.
Methods
Data generation
We generated data assuming a non-experimental design and attempted to answer a
hypothetical study question: “What is the effect of 12-week treatment with statin on lowering
low-density lipoprotein cholesterol (LDL-C)?” We chose this question because the efficacy of
statin on lowering LDL-C has been established87, 88 and patterns of statin use among the
population were extensively studied.89,90,91,92,93 These studies provided the parameters to generate
data close to reality, so the simulation results could be applied to real-world situations.94
Data were generated based on the casual diagram shown in Figure 3.1. In this diagram,
LDL denotes levels of LDL-C, A indicates use of statin, and the subscripts 0, 1, 2 respectively
represent baseline, 6 weeks and 12 weeks after baseline. The hypothetical study population
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included 1,000 patients who were newly-diagnosed with hypercholesterolemia and failed to
control LDL-C through therapeutic lifestyle changes.
At t0, LDL0 was simulated from a normal distribution, with mean 130 mg/dL and
standard deviation 35 mg/dL.95,96,97 For simplicity, we assumed the probability of initiating
treatment at t0, i.e., mean of A0, only depended on levels of LDL0. Specifically, we simulated A0
from a binomial distribution with its mean generated from the following formula:
logit(Pr(A0=1|LDL0))=α0+log(ORLDL-Initiation)×LDL_Level0

(1)

where LDL_Level0 was 0 if LDL0 was less than 160 mg/dL, 1 if LDL0 was between 160 and 190
mg/dL, and 2 if LDL0 was ≥190 mg/dL.87 ORLDL-Initiation was set at 1.5 based on the literature that
higher LDL levels were associated with greater probability of initiating statin treatment.90,98 α0
was set at 0.3146, so that 60% of the study participants initiated treatment at t0.89
At t1, LDL was on average reduced by 30% from LDL0 among those who initiated
treatment at t0, and remained unchanged among those who did not.88,99 A random error was
added to LDL1 so that its standard deviation was around 40 mg/dL. Statin use A1 was generated
separately for those who did not initiate treatment at t0 (i.e., A0=0) and those who did (i.e.,
A0=1). Among those with A0=0, A1 was generated in the same way as A0 using formula (1)
expect that A1 was determined by levels of LDL1 instead of LDL0. For those with A0=1, we
assumed the probability of continuing treatment at t1 (defined as adherence level in our study)
depended on the reduction in LDL from t0 to t1. Specifically, among those with A0=1, A1 was
simulated from a binomial distribution with its mean generated from the following formula:
logit(Pr(A1=1| A0=1, LDL0, LDL1))=γ0+ log(ORLDL-Continuation)×LDL_Red

(2)

where LDL_Red was 0 if reduction in LDL was less than 30% of LDL0, and 1 if the reduction
was greater than 30% of LDL0. Reduction by 30% of LDL0 was the average change in LDL from
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t0 to t1 among those with A0=1, so LDL_Red was actually a dummy variable with value 1
indicating an above-average reduction in LDL. ORLDL-Continuation was set at 1.5, so that patients
with above-average reduction in LDL had 50% higher odds of continuing statin treatment
compared to those with below-average reduction.92,93 γ0 was set at 0.6528, so that 70% of those
with A0=1 continued treatment at t1.91,92
At t2, we assumed that among patients who initiated treatment at t1 (i.e., with A0=0 and
A1=1), LDL on average decreased by 30% from LDL1, which was the same effect size we
specified for treatment initiation at t0 on LDL1; among patients continuing treatment at t1 (i.e.,
with A0=1 and A1=1), LDL on average decreased by 14.3% from LDL1, which corresponded to a
total decrease of 40% from LDL0 after 12-week of treatment88,99; among those discontinuing
treatment at t1 (i.e., with A0=1 and A1=0), LDL on average increased by 42.9% from LDL1, i.e.,
rebounded to the baseline LDL level.100,101 A random variation was added to LDL2 so that its
standard deviation was around 45 mg/dL. Based on these specifications, the true effect size of
12-week treatment with statin was 130 mg/dL×(-40%), i.e., -52 mg/dL.
To assess the performance of different analytic approaches under various scenarios,
besides the basic-case scenario described above, we also generated alternative scenarios with
parameter values varied on the probability of treatment initiation, ORLDL-Initiation, ORLDL-Continuation,
adherence level, effect size and sample size. As shown in Table 3.1, in alternative scenarios, we
generated data with 10% of the patients starting treatment at t0 and t1, ORLDL-Initiation or ORLDLContinuation

equal to 3, adherence level equal to 50%, 60%, 80%, 90% or 100%, effect size equal to

0 or -26, and sample size equal to 200 or 20,000.

Analytic approaches

49

We analyzed the simulated data using IPTW based on four different approaches to
constructing the weight: 1) IPTW assuming intention-to-treat (ITT-IPTW); 2) IPTW assuming
complex mechanism of treatment assignment (Complex-IPTW); 3) IPTW assuming simple
mechanism of treatment assignment (Simple-IPTW); and 4) IPTW assuming invariant
confounders (Invar-IPTW). For the Complex-IPTW, Simple-IPTW, and Invar-IPTW approaches,
we conducted as-treated analyses.40 Complex-IPTW acknowledged that the impact of
confounders on initiating a treatment was different from their impact on continuing the
treatment, whereas Simple-IPTW assumed that confounders had same impact on initiating and
continuing the treatment. Invar-IPTW assumed that time-varying confounders remained
unchanged during the follow-up period. Our review did find some studies performing InvarIPTW analyses, perhaps because they did not collect the time-varying information on potential
confounders.82
The weight construction process of the methods is described in Table 3.2. In analyses
with all four methods, patient-specific weights were first estimated separately at t0 and t1, which
were the unconditional probability of receiving observed treatment divided by the conditional
probability of receiving observed treatment given confounders.19, 20, 37 A patient’s final weight
was the product of his/her weights at t0 and t1.19, 20, 37 In addition, we assumed all methods
correctly recognized the mechanism of treatment initiation at t0 (i.e., Pr(A0|LDL_Level0)), and
thus shared the same process of weight construction at t0. The differences among methods were
in the way of estimating probability of treatment use at t1. ITT-IPTW, Complex-IPTW and
Simple-IPTW correctly modeled the probability of treatment initiation at t1 among patients with
A0=0, i.e., Pr(A1=a1| LDL_Level1), but they differed in estimating the conditional probability of
continuing treatment at t1 among patients with A0=1. ITT-IPTW assumed that the probability of
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continuing treatment was 1, and thus the weight was 1 at t1; Complex-IPTW assumed that
treatment continuation depended on reduction in LDL, which was consistent with the true data
generation process; Simple-IPTW assumed that, same as treatment initiation, treatment
continuation depended on levels of LDL. As for Invar-IPTW, it deviated even further from the
true data degeneration process than Simple-IPTW because it used LDL0 to predict treatment
initiation and continuation at t1.
Probability of receiving treatment given LDL was estimated with logistic regression
models. For instance, the conditional probability of initiating treatment at t1 given levels of LDL1
was estimated using the following logistic model among patients with A0=0:
logit(A1=1| LDL_Level1, A0=0)=η0+ η1× LDL_Level1

(3)

For those with A1=0, the probability of receiving observed treatment was 1 minus the predicted
probability derived from model (3).
After weights were constructed, the second step in each approach was to fit a weighted
structural model to estimate the effect of statin on LDL2. Except using different weights in
different approaches, we used the same linear structural model in all four methods as follows:
LDL2= β0+ β1×A11+ β2×A01+ β3×A10+ ε

(4)

where A11 indicates statin use at both t0 and t1, A10 and A01 respectively indicates statin use only
at t0 and t1. Because ITT-IPTW assumed that no patients discontinued the treatment once they
initiated it, A11 represents treatment initiation at t0, A01 represents treatment initiation at t1 and
A10 is always 0 in ITT-IPTW analyses. The primary parameter of interest in this study is β1,
which estimates the difference between LDL after the study population was treated with statin
for 12 weeks and LDL when none of the population was treated with statin.19
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Assessment of model performance
Under each scenario, we simulated 2,000 datasets, and with each dataset we performed
analyses with the four approaches described above. Each analytic method generated 2,000
estimates under every scenario. We evaluated the validity of different methods using percentage
bias, which was calculated as the difference between the average of 2,000 estimates and the true
effect size, divided by the true effect size.94 To compare the precision of estimates derived from
different methods, we calculated the standard deviation of the 2,000 estimates under each
scenario.94

Results
Overall, 324 scenarios were simulated with parameter values varying on effect size (3
options), sample size (3 options), adherence level (6 options), probability of treatment initiation
(2 options), and associations between LDL and treatment initiation and continuation (3 options).
Performance of the four analytic approaches under various scenarios is shown in Tables 3.3 and
3.4. In these tables, we show results for scenarios with β, n, Pr(A0=1), ORLDL-Continuation and
ORLDL-Initiation set at the basis-case values, as well as scenarios in which we changed one
parameter at a time while keeping all others at their basic values. To fully illustrate the impact of
non-adherence on the performance of different approaches, we reported results for scenarios with
all 6 adherence levels.
Table 3.3 shows the simulated bias in estimates from the four analytic approaches. When
there was no treatment effect, the ITT-IPTW estimates were close to the true effect size
regardless of adherence levels. When the true effect was non-null and the adherence level was
less than 100%, ITT-IPTW estimates were biased towards the null. Bias in ITT-IPTW estimates
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was not influenced by probability of treatment initiation, levels of confounding, sample size or
effect size (results for scenarios with an effect size of -26 were not shown but similar to those
with an effect size of -52). Instead, the extent of bias in ITT-IPTW estimates was linearly
correlated with levels of non-adherence: one percent increase in non-adherence was associated
with approximately one percent increase in the bias in ITT-IPTW estimates.
Complex-IPTW estimates were close to the true effect regardless of effect size or choices
of other parameter values. When the sample size was 200 or ORLDL-Initiation was 3, ComplexIPTW estimates were biased upward for less than 2%. Under all other scenarios shown in Table
3.3, IPTW estimates were biased less than 0.5%. Simple-IPTW estimates were biased
downwards under all scenarios except several scenarios with a sample size of 200 or ORLDLInitiation

of 3. This downward bias became more apparent when ORLDL-Continuation was 3 or as the

level of non-adherence increased. Invar-IPTW estimates were biased upward for most scenarios
shown in Table 3.3. This upward bias became stronger when ORLDL-Initiation was 3, but became
less so when ORLDL-Continuation was 3 or the level of non-adherence increased.
The empirical standard errors of estimates derived from the four approaches are shown in
Table 3.4. Under scenarios with no treatment effect, standard errors of ITT-IPTW estimates
increased when only 10% of the population initiated treatment, or ORLDL-Continuation was 3 (data
not shown), but did not depend on levels of adherence. When the treatment effect was non-null,
standard errors of ITT-IPTW estimates increased along with the levels of non-adherence, and
this relationship was also observed for estimates derived from other three approaches.
Compared to ITT-IPTW estimates, Complex-IPTW estimates had larger standard errors
when there was no treatment effect, but smaller standard errors when the treatment effect was
non-null. Compared to Complex-IPTW estimates, Simple-IPTW estimates had slightly larger
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standard errors under all scenarios except those with no treatment effects, and Invar-IPTW
estimates had slightly larger standard errors under all scenarios except those with a sample size
of 200 or ORLDL-Initiation of 3.

Discussion
Under the realistically constructed scenarios in this study, we demonstrated that ITTIPTW estimates were biased towards to the null when there was non-null treatment effect and
non-adherence after treatment initiation. Interestingly, the extent of bias in ITT estimates
appeared solely depending on the level of non-adherence. One percent decrease in adherence
level among the study sample was associated with one percent increase in the bias in ITT
estimates. IPTW analyses that ignored the complex mechanism or the time-varying nature of
confounders were biased. IPTW analyses that took into account the complex mechanism of
treatment assignment generated approximately unbiased estimates without sacrificing precision.
IPTW assuming a simple mechanism of treatment assignment failed to correctly model
the relationship between LDL and treatment continuation. As such, the negative confounding
bias could not be fully-controlled in the weighted population. As expected, this uncontrolled
confounding bias became more apparent when the impact of LDL on treatment continuation
became stronger (i.e., ORLDL-Continuation=3). Similarly, the weight construction process in IPTW
assuming invariant confounders did not correctly model the relationships of LDL to both
treatment initiation and continuation. As such, the uncontrolled confounding biased the
estimates. As the impact of LDL on treatment initiation increased, a positive bias became more
dominant, and as the impact of LDL on treatment continuation increased, a negative bias became
more dominant.
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Conventional wisdom suggested that IPTW considering the complex mechanisms of
treatment would generate estimates that were more valid but less precise than either ITT or
Simple-IPTW approaches.42 However, we found that estimates derived from a method using
IPTW with the complex mechanisms of treatment actually had smaller standard errors than ITTIPTW estimates when the treatment effect was non-null. The standard error of an IPTW estimate
probably depends on the variation of the constructed weights,20 and variance of study exposure
and mean squared error of the outcome model (if it is a linear regression model).102 Because the
additional incorporation of the probability of treatment continuation in the weight construction
process in Complex-IPTW analyses, weights in Complex-IPTW had a larger variance than those
in ITT-IPTW analyses. This explains the finding that under scenarios with no treatment effect,
the Complex-IPTW estimates had larger standard errors than ITT-IPTW estimates. However,
when there was non-null treatment effect, standard errors of the ITT-IPTW estimate were
probably inflated by the increased mean squared error due to the misspecification of study
exposure in the outcome model.102
It is well-known that ITT estimates are unbiased when there is no treatment effect but
biased towards the null when the effect is non-null.85 However, to our knowledge, this was the
first study that explored the relationship of the extent of bias in ITT-IPTW estimates in relation
to levels of non-adherence and patterns of confounding. Under the causal structure assessed in
our study, after the analyses appropriately controlled for confounding for treatment initiation, for
each one percent decrease in treatment adherence experienced by the sample, the bias in the
average treatment effect increased by one percent. This finding has important implications for
future studies performing ITT-IPTW analyses. First, the bias in ITT-IPTW estimates is nontrivial even if the adherence level is high. For instance, when the adherence level was as high as
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90%, the ITT estimates underestimated the treatment effect by ~10%. This underestimation may
be especially problematic for drug safety studies, because the ITT analysis may miss the harmful
medication effects.85 Second, given the dependence of ITT estimates on adherence levels, we
recommend that studies performing ITT analyses should report adherence measures after
treatment initiation. If provided, findings can be interpreted under appropriate consideration of
the observed adherence patterns.73 Our previous review found that few studies performing ITTIPTW analyses actually did this.82
Our study demonstrated the necessity of taking into account the different relationships
between confounders and different treatment regimens in the process of weigh construction.
Besides the realistic relationships between LDL-C and statin initiation and continuation
illustrated in this simulation, the phenomenon of complex treatment assignment was also noted
by other studies.48,86 For instance, when using IPTW to estimate the effect of aspirin on
preventing cardiovascular disease, Cook et al. found that, potential confounders such as
occurrence of angina and transient ischemic attacks were negatively associated with continuing
treatment with aspirin, but positively correlated with starting aspirin.48 To correctly perform
Complex-IPTW analyses, substantive knowledge regarding the relationships between potential
confounders and different treatment regimens (e.g., initiation, continuation, and resumption, etc)
should guide the specification of treatment models during weight construction. Furthermore, the
findings that IPTW estimates with time invariant confounders were biased due to uncontrolled
confounding emphasized the importance of collecting information on time-varying factors that
predict the study outcomes and also bring about changes in treatment use.85
To our knowledge, this was the first study that explored the impact of various
assumptions made in weight construction on the validity and precision of IPTW estimates.
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Besides simulating data that mimicked a real-world situation, we generated a total 324 scenarios
that varied in parameter values for a range of study characteristics. However, several limitations
must be considered. First, we simulated scenarios with treatment use varying only at two time
points. A real-world longitudinal study will likely involve more time points. If so, it is likely that
treatment assignment mechanisms become more complex than what we simulated. The extent to
which our findings would be generalizable to more complex scenarios remains unknown.
Second, we simulated a continuous variable as the study outcome. Whether or not our findings
extend to different types of outcomes such time-to-event outcomes or categorical outcomes
needs to be explored.
In conclusion, under a range of simulated scenarios, we demonstrated that IPTW
estimates assuming intention-to-treat were biased towards the null when there was non-null
treatment effect and the adherence after treatment initiation was not 100%. This bias was linearly
correlated with non-adherence levels. Studies attempting to estimate the actual effect of a timevarying treatment on a continuous outcome variable should take into account the complex
mechanism of treatment assignment in the process of weight construction.
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Table 3.1. Parameter values used for data generation
Parameter

Meaning

Pr(A0=1)

Probability of starting statin treatment at
baseline or time 1
Odds ratio of starting statin treatment
comparing a higher level LDL to a lower
level LDL
Probability of continuing statin treatment at
time 1 among those on treatment at baseline,
i.e., adherence level
Odds ratio of continuing statin treatment
comparing above-average reduction in LDL
to below-average reduction
Effect size
Sample size

ORLDL-Initiation

Pr(A1=1|A0=1)

ORLDL-Continuation
β
n
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Basic-case
scenario
60% 89

Alternative
scenarios
10%

1.5 90

3

70% 91,92

50%, 60%, 80%
90%, 100%

1.5 92,93

3

52 87,88
1000

0, 26
200, 20000

Table 3.2. Approaches of constructing weights
Modeling approach

Weight construction

ITT-IPTW: Marginal structural models

At t0: w0=Pr(A0=a0)/Pr(A0=a0| LDL_Level0)

assuming intention-to-treat

At t1: If A0=0, w1= Pr(A1=a1)/Pr(A1=a1|LDL_Level1);
If A0=1, w1=1
Final weight: wfinal= w0× w1

Complex-IPTW: Marginal structural

At t0: w0=Pr(A0=a0)/Pr(A0=a0| LDL_Level0)

models assuming complex mechanism of

At t1: If A0=0, w1*= Pr(A1=a1)/Pr(A1=a1| LDL_Level1);

treatment assignment

If A0=1, w1*= Pr(A1=a1)/Pr(A1=a1| LDL_Red)
Final weight: wfinal*= w0× w1*

Simple-IPTW: Marginal structural models

At t0: w0=Pr(A0=a0)/Pr(A0=a0| LDL_Level0)

assuming simple mechanism of treatment

At t1: If A0=0, w1**= Pr(A1=a1)/Pr(A1=a1| LDL_Level1);

assignment

If A0=1, w1**= Pr(A1=a1)/Pr(A1=a1| LDL_Level1)
Final weight: wfinal**= w0×w1**

Invar-IPTW: Marginal structural models

At t0: w0=Pr(A0=a0)/Pr(A0=a0| LDL_Level0)

assuming invariant confounders

At t1: If A0=0, w1***= Pr(A1=a1)/Pr(A1=a1| LDL_Level0);
If A0=1, w1***= Pr(A1=a1)/Pr(A1=a1| LDL_Level0)
Final weight: wfinal***= w0× w1***

Pr(At=at): unconditional probability of receiving observed treatment at time t.
LDL_Levelt was 0 if LDLt was <160, 1 if 160 ≤ LDLt ≤190, and 2 if LDLt was ≥190.
LDL_Red was 0 if LDL0-LDL1 was ≤ 30% of LDL0, and 1 if LDL0-LDL1 was greater than 30% of LDL0.
Bold texts highlight the differences in weight construction among approaches.
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Table 3.3. Simulated bias in four analytic approaches with marginal structural models under various scenarios

β

Pr(A0=1
)

ORLDL

ORLDL-

-Initiation

Continuation

0
0
0
0
0
0
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52

60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
10%
10%
10%
10%
10%
10%
60%
60%
60%
60%
60%
60%
60%
60%

1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
3
3
3
3
3
3
1.5
1.5

1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
3
3

n

Pr(A1=1
|A0=1)
(%)

1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000

100
90
80
70
60
50
100
90
80
70
60
50
100
90
80
70
60
50
100
90
80
70
60
50
100
90

ITT-IPTW

ComplexIPTW*

Bias
(%)
0.1
0.1
0.1
0.1
0.1
0.1
-51.9
-46.5
-41.2
-35.9
-30.6
-25.4
-52
-46.6
-41.2
-35.9
-30.6
-25.4
-51.3
-45.9
-40.6
-35.3
-30
-24.8
-51.9
-46.2
60

-------0.2
-10.6
-20.8
-31
-41.2
-51.2
-0.1
-10.5
-20.7
-31
-41.2
-51.2
-1.3
-11.7
-22
-32.2
-42.3
-52.3
-0.2
-11.1

Bias
(%)

SimpleIPTW*
Bia
s
(%)

InvarIPTW*
Bias
(%)

0.1
0.1
0.1
0.1
0.2

------

0
-0.2
-0.4
-0.6
-0.7

------

1.8
1.4
1.0
0.7
0.3

------

-51.9
-51.9
-51.9
-51.9
-51.9

-0.2
-0.2
-0.2
-0.2
-0.3

-52.2
-52.5
-52.8
-53.0
-53.3

0.3
0.9
1.5
2.0
2.5

-50.2
-50.5
-50.8
-51.1
-51.4

-3.5
-2.9
-2.3
-1.7
-1.1

-52
-52
-52
-52
-51.9

0
-0.1
0
-0.1
-0.1

-52.3
-52.6
-52.9
-53.2
-53.5

0.6
1.1
1.7
2.3
3.0

-51.9
-52.2
-52.5
-52.8
-53.1

-0.1
0.4
1.0
1.5
2.1

-51.3
-51.3
-51.3
-51.3
-51.3

-1.3
-1.3
-1.3
-1.3
-1.3

-51.6
-51.9
-52.2
-52.5
-52.7

-0.8
-0.2
0.4
0.9
1.4

-46.5
-46.8
-47.2
-47.5
-47.8

-10.5
-9.9
-9.3
-8.7
-8.1

-51.9

-0.2

-52.6

1.2

-50.7

-2.6

-52
60%
1.5
1000
3
-52
60%
1.5
1000
3
-52
60%
1.5
1000
3
-52
60%
1.5
1000
3
-52
60%
1.5
1.5
200
-52
60%
1.5
1.5
200
-52
60%
1.5
1.5
200
-52
60%
1.5
1.5
200
-52
60%
1.5
1.5
200
-52
60%
1.5
1.5
200
-52
60%
1.5
1.5
20,000
-52
60%
1.5
1.5
20,000
-52
60%
1.5
1.5
20,000
-52
60%
1.5
1.5
20,000
-52
60%
1.5
1.5
20,000
-52
60%
1.5
1.5
20,000

β is the mean of effect estimates from 2,000 trials.

Bias (%)= [∑ ( β − β ) / β ×100%] / 2000 .

80
70
60
50
100
90
80
70
60
50
100
90
80
70
60
50

-40.7
-35.2
-29.8
-24.5
-51.2
-45.9
-40.5
-35.2
-29.9
-24.7
-52
-46.6
-41.3
-36
-30.7
-25.5

-21.8
-32.4
-42.7
-52.8
-1.5
-11.8
-22.1
-32.3
-42.5
-52.4
0
-10.4
-20.6
-30.9
-41
-51

-51.9
-51.9
-51.9
-51.9

-0.2
-0.2
-0.2
-0.3

-53.3
-54.1
-54.9
-55.6

2.6
4.0
5.5
6.9

-51.5
-52.3
-53.1
-53.9

-1.0
0.6
2.2
3.7

-51.2
-51.2
-51.2
-51.2
-51.1

-1.5
-1.5
-1.5
-1.5
-1.7

-51.5
-51.8
-52.2
-52.5
-52.8

-1.0
-0.3
0.4
0.9
1.5

-49.5
-49.8
-50.1
-50.4
-50.7

-4.8
-4.2
-3.6
-3.0
-2.5

-52
-52
-52
-52
-52

0
0
0
0
0

-52.3
-52.5
-52.8
-53.1
-53.4

0.5
1.0
1.6
2.1
2.6

-50.3
-50.6
-50.9
-51.2
-51.5

-3.3
-2.7
-2.1
-1.5
-0.9

* Estimates from Complex-IPTW, Simple-IPTW and Invar-IPTW were same as ITT-IPTW estimates in scenarios with 100%
adherence.
-- When the true effect size was zero, the percentage of bias could not be calculated.
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Table 3.4. Simulated standard errors of estimates from four analytic approaches of marginal
structural models under various scenarios
β

0
0
0
0
0
0
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52
-52

Pr(A0=1
)

ORLDL-

ORLDL-

Initiation

Continuation

60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
10%
10%
10%
10%
10%
10%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%
60%

1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
3
3
3
3
3
3
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5

1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
3
3
3
3
3
3
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5

n

1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
200
200
200
200
200
200
20,000
20,000
20,000
20,000
20,000
20,000

Pr(A1=1|
A0=1)
(%)
100
90
80
70
60
50
100
90
80
70
60
50
100
90
80
70
60
50
100
90
80
70
60
50
100
90
80
70
60
50
100
90
80
70
60
50
100
90
80
70
60
50

ITTIPTW

ComplexIPTW*

SimpleIPTW*

InvarIPTW*

3.15
3.22
3.29
3.37
3.49

3.12
3.17
3.22
3.28
3.38

3.25
3.30
3.37
3.47
3.60

2.99
3.03
3.08
3.12
3.18

2.99
3.04
3.09
3.15
3.23

3.09
3.13
3.18
3.24
3.34

3.40
3.55
3.84
4.06
4.41

3.41
3.60
3.92
4.21
4.60

3.38
3.56
3.84
4.11
4.46

6.38
6.41
6.43
6.45
6.47

6.39
6.41
6.44
6.46
6.49

4.68
4.71
4.75
4.80
4.87

2.98
3.03
3.07
3.12
3.22

2.99
3.04
3.08
3.14
3.23

3.09
3.14
3.18
3.25
3.35

7.58
7.69
7.78
7.85
8.03

7.59
7.71
7.78
7.88
8.11

7.48
7.57
7.65
7.77
7.96

0.67
0.68
0.69
0.70
0.72

0.67
0.68
0.69
0.71
0.72

0.71
0.71
0.72
0.74
0.75

3.10
3.10
3.10
3.10
3.10
3.10
2.97
3.05
3.13
3.22
3.26
3.27
3.25
3.89
4.32
4.59
4.75
4.89
6.36
6.38
6.39
6.44
6.48
6.47
2.96
3.06
3.17
3.23
3.27
3.30
7.54
7.78
7.92
8.05
8.09
8.13
0.67
0.69
0.71
0.72
0.73
0.74

Standard error is the standard deviation of the estimates from 2,000 trials.
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*Standard errors of estimates from Complex-IPTW, Simple-IPTW and Invar-IPTW were same
as those of ITT-IPTW estimates in scenarios with 100% adherence.
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LDL0

LDL1

LDL2
A0

A1

Figure 3.1. The causal diagram guiding data generation.
LDL denotes levels of low-density lipoprotein cholesterol, A indicates use of statin medication,
and the subscripts 0, 1, 2 represent baseline, 6 weeks and 12 weeks after baseline, respectively.
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Chapter 4: Long-term effects of glucosamine and chondroitin on treating knee
osteoarthritis: An analysis with marginal structural models
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Abstract
Objectives: The purpose of this study was to estimate the long-term effectiveness of
glucosamine and chondroitin in relieving knee symptoms and slowing disease progression
among patients with knee osteoarthritis (OA).
Methods: The 4-year follow-up data from Osteoarthritis Initiative were analyzed. We used a
“new-user” design, for which only participants who were not using glucosamine/chondroitin at
baseline were included in analyses (n=1,625). Cumulative exposure was calculated as the
number of visits when participants reported use of glucosamine/chondroitin. Knee symptoms
were measured with WOMAC Pain, Stiffness and Physical Function, and structural progression
of OA was measured with joint space width (JSW). Sociodemographic characteristics and
indices of disease severity were considered as potential confounders. To take into account that
the indices of disease severity may be simultaneously confounders and intermediate variables,
we used marginal structural models to estimate the long-term treatment effects.
Results: During the study period, 18% of the participants initiated treatment with
glucosamine/chondroitin and 4% reported use at all assessments. After adjustment for potential
confounders with marginal structural models, we found no clinically significant differences
between users at all assessments and never-users of glucosamine/chondroitin in WOMAC Pain:
0.68 (95% CI: -0.16 to 1.53); WOMAC Stiffness: 0.41 (95% CI: 0 to 0.82); WOMAC Function:
1.28 (95% CI: -1.23 to 3.79); or JSW: 0.11 (95% CI: -0.21 to 0.44).
Conclusions: Long-term use of glucosamine/chondroitin did not appear to relieve symptoms or
modify disease progression among radiographically confirmed patients with OA. Our findings
are consistent with the results from recent long-term clinical trials.

66

Introduction
Osteoarthritis (OA) is the most common type of arthritis and a leading cause of pain and
physical disability in older adults.1 Although currently no effective remedies for OA exist,
clinical guidelines recommend both pharmacological and non-pharmacological therapies to
relieve symptoms.103 In the United States, glucosamine and chondroitin are two dietary
supplements that are commonly used among patients with OA.8 Both glucosamine and
chondroitin are essential components of the proteoglycans in normal cartilage and were
purported to provide substrate for the biosynthesis of proteoglycans.104 In vitro and animal
studies suggest that glucosamine and chondroitin simulate the synthesis of proteoglycans and
inhibit the synthesis of proteolytic enzymes that lead to the premature breakdown of
cartilage.105,106
Despite the biologic plausibility, evidence regarding the efficacy of glucosamine and
chondroitin in relieving OA symptoms and modifying structural progression is not established.
Several meta-analyses which pooled results from existent randomized clinical trials that assessed
symptomatic benefits reported substantial heterogeneity in findings across studies.11, 107-109
Differences in study quality, preparation of the interventions, industry involvement and study
size may have explained the observed heterogeneity.11, 107-109 Large-scale trials with high quality
and little connection to industry often reported a much smaller effect size of symptoms relief
than earlier small industry-funded studies.107,108 Regarding the efficacy of glucosamine and
chondroitin in modifying disease progression, several meta-analyses reported small to moderate
effect sizes and studies with longer intervention periods demonstrated a stronger effect of
glucosamine on slowing joint space narrowing than studies with a shorter treatment period.110,111
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The purpose of this study was to quantify the effectiveness of glucosamine and
chondroitin in relieving OA symptoms and modifying structural progression. This study is
warranted for several reasons. First, in the United States, glucosamine and chondroitin are
almost always sold in a combination pill.112 Despite the extensive research on single treatment
with glucosamine or chondroitin, studies of the combined treatment are sparse.113 Second, to our
knowledge, the longest studies were three-year trials conducted more than a decade ago in
Europe and supported by one pharmaceutical company.12,13 The Osteoarthritis Initiative (OAI)
provides a unique opportunity to examine the long-term effectiveness of glucosamine and
chondroitin on treating OA, because it administered comprehensive measurements on treatment
use and changes in knee symptoms and joint structure for up to four years.16 Third, efficacy
evidence of a treatment derived from clinical trials is often limited in generalizability because
they often use strict study protocols and highly selected patients and are typically conducted at
large medical centers.114 Non-experimental studies, on the other hand, can provide clinicians and
patients with a more realistic expectation for treatment benefits in real-world environments.114
We are aware of one non-experimental study which assessed the impact of glucosamine and
chondroitin on slowing structural progression.115 Our study used different designs and analytic
methods and extended their work by assessing both symptoms relief and reduction in structural
progression.

Methods
The Institutional Review Boards of the University of Massachusetts Medical School and
the Memorial Hospital of Rhode Island approved this study.
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Data source and study sample
This study used publicly available data from the OAI (http://oai.epi-ucsf.org/). From
2004 to 2006, four study sites (i.e., Baltimore, MD; Columbus, OH; Pittsburgh, PA; and
Pawtucket, RI) enrolled 4,796 residents who had established or were at high risk for developing
knee OA.16 The detailed OAI protocol can be found elsewhere.16 Follow-up information for up
to four years was used (the dataset version numbers are 0.2.2, 1.2.1, 3.2.1, 5.2.1, and 6.2.2).
Inclusion/exclusion criteria are shown in Figure 4.1. We included OAI participants with
radiographic knee OA at enrollment, i.e., those with a Kellgren-Lawrence (K-L) grade of 2 or
greater in at least one knee (n=2,539).
To improve study validity, we used a “new-user” design,116 for which only participants
not reporting use of glucosamine or chondroitin at baseline were included in analyses (n=1,731).
From this group, we then identified two samples: 1) for analysis of symptoms and 2) for the
analysis of structural changes. For the analysis of symptoms, we also excluded participants with
missing data on key confounders at baseline (n=44) and those missing exposure or outcome data
at year 1 of the study (n=62). When analyzing structural progression, we excluded persons with
following characteristics: 1) end-stage OA (i.e., K-L grade 4) or primary joint space narrowing in
the lateral tibiofemoral compartment at baseline (n=150); 2) missing measures of joint space
width (JSW) or JSW measures with a poor alignment of the tibial plateau at baseline (n=169); or
3) missing key confounders at baseline (n=37) or exposure or outcome at year 1 (n=262). The
remaining 1,625 participants with 4,264 person-visits contributed to the analyses of symptoms,
and 1,113 participants with 2,367 person-visits were included in analyses of structural changes.

Exposure definition
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Use of glucosamine and chondroitin was defined based on self-reported information. At
baseline and annual follow-up visits, participants were asked “During the past 6 months, did you
use the following health supplements for joint pain or arthritis?” with separate questions for
glucosamine and chondroitin sulfate use. We considered a participant taking glucosamine or
chondroitin if he/she reported using it for at least 4 days per week, and not taking the supplement
if they reported not using it or using it for less than 4 days per week. Throughout the study
period, ~90% of the participants taking either one of the supplements were taking both
concurrently. So at each visit we defined use of glucosamine/chondroitin as taking either of these
supplements. To estimate the long-term treatment effects, we calculated the cumulative
exposure by summing the number of visits when participants reported using
glucosamine/chondroitin.

Assessment of OA symptoms
If both knees had radiographic OA, we used measurements from the knee with more
severe pain at baseline. OA symptoms and function were assessed annually with Western
Ontario and McMaster Universities Arthritis Index (WOMAC) (the Likert version 3.1).
WOMAC measures three separate domains: Pain (5 items), Stiffness (2 items), and Physical
Function (17 items).117 Each scale item uses a range of 5 Likert responses, ranging from
‘0=none’ to ‘4=extreme’. Responses to items in each domain were summed to produce subscale
score, which ranges from 0~20 for Pain, 0~8 for Stiffness and 0~68 for Physical Function.
Larger WOMAC scores represent worse symptoms or knee-related function.

Assessment of JSW
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If both knees had radiographic OA, we used measures from the knee with narrower space
width in the medial tibiofemural joint at baseline. Joint structural progression was measured
with changes in medial JSW during follow-up from baseline. All participants at baseline and
annual visits had bilateral standing knee x-rays obtained in posterior anterior projection with
knees flexed to 20-30 degrees and feet internally rotated 10 degrees.16 Longitudinal
measurements of JSW from serial knee x-rays were conducted through a customized software
tool, which automatically delineated the margin of the femoral condyle and the tibial plateau.118
Multiple JSWs were measured at fixed locations along the joint. An anatomical coordinate
system, which extended from the medial end (x=0) to the lateral end (x=1) in the joint space, was
defined to facilitate an objective determination of measurement location. We chose the JSW
measure at x=0.25 (in the medial compartment) because it was demonstrated to have best
responsiveness to changes.119
At each assessment of JSW, the distance from tibial plateau to tibial rim closest to
femoral condyle was measured to indicate knee positioning.120 To take into account the potential
error in JSW measurement due to poor knee positioning at a single visit or inconsistent
positioning between visits, we did not use the JSW measures (i.e., considered them missing) if
the plateau to rim distance was larger than 6.5 mm or change in this distance between visits was
greater than 2 mm.120 Among the 431 persons who were excluded at baseline (n=169) and year 1
(n=262) due to not having a valid measure of exposure or JSW (shown in Figure 4.1), 355 (82%)
were excluded due to a poor or inconsistent knee positioning at JSW measurement. An
additional 181 persons had inconsistent knee positioning for ≥1 assessment at year 2 to year 4.
The probability of having a potentially erroneous JSW measure at following assessments was
comparable among users (10.7%) and non-users (11.4%) of glucosamine/chondroitin.
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Measurement of potential confounders
The following variables were considered potential confounders: sociodemographics,
clinical characteristics of OA, indices of general health status, body mass index (BMI), and use
of treatments other than glucosamine/chondroitin. Our previous work has shown that use of
glucosamine and chondroitin was more prevalent among older adults, women, non-Hispanic
Whites, individuals with higher education or higher income.8 Income was defined as personal
family income for the last year, including all sources such as wages, salaries, social security and
retirement benefits.
OAI administered comprehensive measurements on participants’ clinical characteristics,
including knee alignment,121 symptom-related multi-joint OA,122 K-L grade,122 and history of
having a knee injury or surgery.123 Knee alignment was measured with goniometer, and varus or
valgus deformity was recorded if malalignment was found. We considered symptom-related
multi-joint OA present if participants had OA symptoms in at least two joints other than knee.124
Information was also collected on history of having a knee injury that limited ability to walk for
at least two days, and history of having knee surgery including arthroscopy, ligament repair or
meniscectomy.
The 12-item Short-Form Health Survey (SF-12) provided an assessment of general health
status.125 Answers to the 12 questions were combined to generate Physical and Mental
Component Summary scores, which range from 0 to 100, with higher scores indicating better
health status. BMI has been reported as a risk factor for OA progression due to its potential local
biomechanical effect and systemic metabolic effect.126 We calculated BMI from measured
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height and weight [weight (kg)/height (m2)]. Participants with a BMI less than 25 were defined
as having normal weight, 25 and less than 30 as overweight, and 30 and over obese.
Trained interviewers obtained information about use of other arthritis treatments,
including conventional medications and complementary and alternative medicine (CAM). At
each visit, separate dummy variables were generated to indicate use of acetaminophen, nonsteroidal anti-inflammatory agents (NSAIDs) and opioids in the past 30 days. Use of
acetaminophen and NSAIDs included use of prescriptions and/or over-the-counter medications.
Use of CAM, which was surveyed at baseline and year 2, covered therapies commonly used in
the United States, including alternative medical systems, mind-body interventions, manipulation
and body-based methods, energy therapies and biologically based therapies.127
Sociodemographics and history of a knee surgery were considered invariant and all other
potential confounders were considered time-varying during the study period. For participants
missing information on the time-varying variables, we imputed missing values with the last
observation carried forward.128

Statistical analyses
We first described baseline sociodemographic and clinical characteristics of study
participants by status of glucosamine/chondroitin use at year 1. When estimating the long-term
effects of glucosamine/chondroitin use, we chose marginal structural models (MSMs) as the
primary analytic method because we hypothesized that the data structure involved time-varying
confounders that were influenced by previous treatments.19 Figure 4.2 depicts the hypothesized
relationships between glucosamine/chondroitin use, study outcomes, and potential time-varying
confounders. Previously measured study outcomes and time-varying confounders may be
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simultaneously confounders and intermediate variables. For instance, when studying WOMAC
Pain as the outcome, the Pain score measured at the previous visit can be a potential confounder
because it correlates with Pain score measured at current visit and patients with more severe pain
are more likely to use glucosamine/chondroitin.8 Furthermore, if glucosamine/chondroitin is
effective in relieving pain (which is a hypothesis tested in our study), the previously measured
Pain score lies on the causal path from prior treatment use and currently measured WOMAC
Pain. If so, standard regression models adjusting for previous pain severity will produce biased
estimates of the long-term treatment effects.17
MSMs rely on inverse probability weighting to adjust for time-varying confounding.19
At each visit, we estimated the conditional probability of receiving observed treatment with
glucosamine/chondroitin given baseline characteristics and time-varying confounders (including
WOMAC subscale, K-L grade, SF-12 subscales, BMI, knee alignment, prior incidence of knee
injury, use of analgesics and CAMs) that were measured at the same visit as use of
glucosamine/chondroitin. For each specific WOMAC outcome, we adjusted for only the same
previously-measured subscale as potential confounder. When analyzing JSW, we adjusted for
previously measured WOMAC Pain because we found it a stronger correlate with treatment use
than Stiffness and Physical Function.8
The inverse of the conditional probability was stabilized with the conditional probability
of receiving observed treatment given baseline covariates. Conditional probabilities in
numerator and denominator were estimated with logistic regression models (i.e., treatment
models).19 To take into account that associations of confounders to treatment initiation may be
different from their associations to treatment continuation, we fit treatment models stratified by
previous treatment status.42 Specifically, the treatment models estimated the probability of
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initiating treatment among those not using treatment at previous visit and the probability of
continuing the treatment among those reporting use at previous visit.
Patients were excluded from analyses at the first occurrence of loss-to-follow-up,
undergoing total knee replacement, or missing information on glucosamine/chondroitin use or
outcome, whichever came first. To address the potential bias from informative dropout, we
incorporated inverse-probability-of-censoring weighting in analyses.19 At each visit from year 2
to year 4, “censoring” status was categorized as follows: 1) not censored; 2) censored due to
illness/death/total knee replacement; 3) censored due to refusal to participate/loss of
contact/missing exposure or outcome. Censoring weights were calculated in the same way as
treatment weights, except that multinomial logistic models were used to estimate the probability
of having observed censoring status and that current treatment use was added in the censoring
models.19 The final weights were the products of visit-specific treatment weights and censoring
weights.19 To ameliorate the impact of potential positivity violations, we truncated the final
weights at the 99th percentile.20
After weights were constructed, weighted linear models (i.e., outcome models) were fit to
estimate the relationships between cumulative exposure to glucosamine/chondroitin up to
previous visit and changes in WOMAC scores and JSW measured at current visit.19 In addition
to the cumulative treatment use, baseline variables were also included in these outcome
models.19 We fit the outcome models using the GENMOD procedure in SAS (with an
“independent” correlation structure and using “robust” standard errors).37 Under the assumptions
of no unmeasured confounding and correct specifications of the treatment and outcome models,
the MSM estimates represent the causal effects of using glucosamine/chondroitin for 1, 2 and 3
years on WOMACs and JSW among the study population.19 Previous validation studies 129-133
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suggest the minimal clinically-important improvement ranged from -4.6 to -1.2 for WOMAC
Pain, -1.5 to -0.5 to for WOMAC Stiffness, -9.9 to -4.1 to for WOMAC Physical Function, and
0.2 to 0.5 mm for JSW.
We also compared the MSM estimates with the estimates derived from analyses with
generalized estimating equations (GEE). In GEE analyses, we adjusted for baseline and timevarying confounders in the model and chose the working correlation structure that maximized
the quasi-likelihood information criterion.134 We hypothesized that, if there is treatment effect
that is mediated by the time-varying confounders, GEE estimates would be smaller in magnitude
than the MSM estimates because GEE analyses cannot correctly estimate such mediated effect.19

Results
Characteristics of study sample
Table 4.1 shows the baseline characteristics of the 1,625 participants included in analyses
of WOMACs by status of glucosamine/chondroitin use at year 1. Overall, 43.6% were aged ≥65
years, 58.0% were women, 72.9% were non-Hispanic White and 37.8% had K-L grade 3 or 4.
Ten percent of non-users at baseline initiated glucosamine/chondroitin at year 1. Compared to
non-initiators of glucosamine/chondroitin at year 1, initiators tended to be younger, have higher
education attainment and higher income, and were more likely to use other CAM and have a
BMI ≥25 kg/m2 and valgus deformity at baseline. Similar trends were found in the study sample
for the JSW analyses.

Predictors of glucosamine/chondroitin use
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Around 18% of participants initiated glucosamine/chondroitin during the study period.
Among these initiators, 22.8% reported treatment use at all assessments (other than baseline) and
38.4% discontinued the treatment at a later assessment. Table 4.2 shows the correlates of
initiating and continuing glucosamine/chondroitin treatment. Older adults were less likely to
initiate treatment, but more likely to stay on treatment once they initiated it. Longitudinally,
participants were less likely to initiate treatment (comparing year 3 and year 2 with year 1), but
more likely to continue the treatment (comparing year 3 with year 2). Being overweight, having
K-L grade 3/4 and using NSAIDs were correlates of treatment initiation, while use of other CAM
methods and acetaminophen was associated with both initiating and continuing treatment.
When analyzing WOMAC Pain as outcome, the mean of final weights was 1.00, and the
maximum value was 5.92 and 99th percentile was 1.83. Final weights for analyses of Stiffness
and Function had similar distributions. The final weights for analyzing JSW had a mean of 0.99
and ranged from 0.13 to 4.92.

Effects of glucosamine/chondroitin on treating knee OA
As shown in the top section in Table 4.3, after adjustment for potential confounders with
MSMs, compared to participants who never reported previous use of glucosamine/chondroitin,
those reporting use for three, two and one assessments had on average 0.68 points increase (95%
CI: -0.16 to 1.53), 0.12 points decrease (95% CI: -0.71 to 0.48) and 0.28 points increase (95%
CI: -0.08 to 0.65) in WOMAC Pain, respectively. In terms of WOMAC Stiffness and Function,
the average differences in changes from baseline between participants using the treatment at all
assessments and never-users were 0.41 (95% CI: 0 to 0.82) and 1.28 (95% CI: -1.23 to 3.79),
respectively. The bottom section in Table 4.3 shows the estimates of treatment effects on JSW.
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After adjustment for confounders with MSMs, compared to never-users, those who reported
previous use for three, two and one assessments had on average 0.11mm wider (95% CI: -0.21 to
0.44), 0.14mm wider (95% CI: -0.07 to 0.35) and 0.03mm narrower (95% CI: -0.16 to 0.10) in
medial JSW, respectively.

Discussion
Following a large sample of participants with knee OA who were “naïve” to treatment
with glucosamine/chondroitin, we found that around 18% initiated the treatment and 4% reported
use at all assessments during the study period. Age, BMI levels, K-L grade and use of other
treatments were important correlates of initiating and/or continuing glucosamine/chondroitin
treatment. After adjustment for potential confounders with MSMs, we found that treatment with
glucosamine/chondroitin for three years did not appear to bring about relief in symptoms or
retardation of disease progression. Analyses with GEE yielded similar results as the MSM
analyses.
Our data relating to symptomatic effects are consistent with recent systematic
reviews11,107 on single treatment with glucosamine or chondroitin and with independent longterm clinical trials on combination treatment with both supplements.135,136 The recently updated
Cochrane review concluded that clinical trials with adequate allocation concealment did not
demonstrate a superiority of glucosamine over placebo for pain or physical function.11 Likewise,
a recent meta-analysis found that large-scale clinical trials using an intention-to-treat analysis
reported minimal or nonexistent symptomatic benefits from chondroitin compared to placebo.107
Moreover, as far as we know, there are two published long-terms trials, i.e., the
Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) 135 and the Long-term Evaluation
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of Glucosamine Sulfate (LEGS) study,136 which assessed the efficacy of combination treatment
with both supplements in treating knee OA. Both studies found that combination treatment did
not confer symptomatic benefits compared to treatment with either supplement or with
placebo.135,136 Our data join a growing body of evidence suggesting that
glucosamine/chondroitin has no impact on relieving OA symptoms.
With respect to the effect of glucosamine/chondroitin on structural progression, our
findings are consistent with some,14 but not all of the literature.115,136 The GAIT study reported a
difference of 0.028mm in joint space narrowing between the combination treatment group and
the placebo group and concluded no benefits of modifying disease progression from combination
treatment.14 On the contrary, the LEGS study found that the difference in joint space narrowing
was 0.10mm after two-year follow-up, which was in favor of the combination treatment and was
marginally statistically significant (p=0.046). This absolute reduction in joint space narrowing
was comparable to that found in our study. Considering that the smallest detectable change in
JSW measures was 0.2 mm,132 this reduction may be trivial.
Moreover, we are aware of another non-experimental study by Martel-Pelletier et al.,
which was based on OAI participants and assessed use of glucosamine/chondroitin on slowing
OA progression.115 Using a different study design and analytic approaches, our study confirms
their finding that combination use of glucosamine and chondroitin does not have an impact on
slowing joint space narrowing. However, their study reported that glucosamine and chondroitin
reduced loss of cartilage volume in some subregions of the tibiofemoral joint assessed with
MRI.115 We interpret this conclusion cautiously. Over 60 comparisons were conducted to
compare cartilage volume loss in different subregions of the knee joint between users and nonusers of glucosamine/chondroitin, but no adjustments for multiple comparisons were made. Once
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Bonferroni corrections were applied,137 none of the comparisons would have been statistically
significant.
Our study has some merits that are worth mentioning. First, we used a new-user design
by excluding participants using glucosamine/chondroitin at baseline. A new-user design is
considered a gold standard in pharmacoepidemiologic studies due to the well-recognized
advantages of studying initiators of treatments.73 In particular, a new user design can avoid the
selection of prevalent users who are responsive to the treatment and thus prevent overestimating
the treatment benefits.73,116 In addition, a new-user design can avoid bias from adjusting for
confounders that may be affected by previous treatments in prevalent users.73,116 Second, we
used MSMs to estimate causal effects by adjusting for time-varying confounders which may also
be intermediate variables and by controlling for bias from potential informative dropout.17,19
GEE models generally produce associative effects and may estimate causal effects under very
stringent assumptions, including the assumption that time-varying confounders are not
influenced by prior treatments.17,19 GEE adjusts for time-varying confounders through
conditioning analysis on these covariates and thus eliminates any indirect effect from prior
treatments that are mediated by the time-varying confounders.17,19 Unlike GEE, MSM adjusts
for time-varying confounders through assigning weights to participants and thus is capable of
estimating overall treatment effects, if they exist.17,19
Notwithstanding, our findings must be considered with limitations in mind. First, there
may be misclassification in use of glucosamine/chondroitin. Treatment use was assessed
annually, and it is likely that participants were on and off the treatment during the intervals of
assessments. If this misclassification was non-differential, we would have underestimated the
treatment effects. Moreover, we do not have information on treatment dosage or the extent of
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purity of the supplements. The supplements evaluated in our study were likely over-the-counter
products, which have been reported to be different from those tested in clinical trials in terms of
quality, strength, and composition.138 Finally, despite that OAI administered comprehensive
measurement on the disease severity that might affect patients in seeking treatment and that these
indices were adjusted to deal with the potential confounding by indication, we could not rule out
the possibility that our findings may still be biased by unmeasured confounding.
In summary, long-term use of glucosamine/chondroitin as dietary supplements did not
appear to relieve symptoms or modifying disease progression among radiographically confirmed
OA patients. Our findings are consistent with the results from recent long-term clinical trials and
support the latest guidelines for OA treatment which recommend against using the nutritional
supplements of glucosamine and chondroitin.103
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Table 4.1. Baseline characteristics by use of glucosamine/chondroitin at year one among persons
with radiographic knee OA (n=1,625)
Characteristics

Total

60.0

Non-initiators of
glucosamine/
chondroitin
(n=1,460)
Percentage
56.0

65-74

32.7

31.6

31.7

≥75

7.3

12.4

11.9

57.0

58.1

58.0

Non-Hispanic White

72.1

73.0

72.9

Non-Hispanic Black

23.0

24.1

24.0

Other

4.9

3.0

3.1

High school or less

19.4

20.8

20.6

Some college

20.6

27.0

26.3

College graduate

17.0

20.8

20.4

Graduate school

43.0

31.4

32.6

<25,000

17.6

17.5

17.5

25,000 - 50,000

23.0

29.5

28.9

>50,000

59.4

53.0

53.7

KL grade 3 or 4

37.6

37.8

37.8

Symptom-related multi-joint OA

49.1

49.4

49.4

Use of non-steroidal antiinflammatory agents
Use of acetaminophen

42.4

35.4

36.1

12.1

13.9

13.7

Use of opioids

6.1

6.1

6.1

Use of complementary and
alternative medicine
History of knee injury

35.8

24.4

25.5

37.0

37.7

37.6

73.3

70.8

29.0

8.5
42.4
49.1

15.7
37.5
46.8

15.0
38.0
47.0

Normal

24.9

26.5

26.3

Varus

24.2

28.0

27.6

Age (years)
<65

Women

Glucosamine/
chondroitin
initiators (n=165)

56.4

Ethnicity/Race

Education

Income ($)

History of knee surgery
Body Mass Index (kg/m2)
<25
25 - <30
≥30
Knee alignment
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Valgus
WOMAC Pain
WOMAC Stiffness
WOMAC Physical Function
SF-12 Physical Component Score
SF-12 Mental Component Score
Medial joint space width (mm)*

50.9
4.2 (3.9)
2.2 (1.8)
12 (11.8)
48.1 (8.8)
54.6 (7.9)
5.2 (1.3)

45.5
Mean (Standard Deviation)
3.8 (4.1)
2 (1.8)
12 (13)
47.6 (9.6)
53.3 (8.5)
5.2 (1.2)

46.0
3.9 (4.1)
2 (1.8)
12 (12.9)
47.7 (9.5)
53.4 (8.4)
5.2 (1.2)

*Based on information on 1,113 participants included in JSW analyses, among which 107
reported initiating glucosamine/chondroitin at year 1.
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Table 4.2. Correlates* of glucosamine/chondroitin use in the three-year follow-up period among
persons with radiographic knee OA
Correlates of treatment use

Baseline characteristics
Age: 75 vs <65 years
Age: 65-74 vs <65 years
Women vs men
Black vs White
Other race vs White
Graduate education vs High school
College graduate vs High school
Some college vs High school
Income ($): >50 k vs <25k
Income ($): 25-50k vs <25k
History of knee surgery
Time-varying confounders
(concurrent)
Year 3
Year 2

Adjusted odds ratios§
(95% CI) of
"initiating" treatment

Adjusted odds ratios§
(95% CI) of
"continuing" treatment

0.63 (0.40-0.99)
0.71 (0.53-0.95)
0.89 (0.68-1.17)
0.74 (0.53-1.03)
1.02 (0.53-1.97)
1.60 (1.07-2.38)
1.21 (0.78-1.86)
0.91 (0.61-1.36)
0.99 (0.65-1.51)
0.93 (0.62-1.41)
0.78 (0.58-1.05)

2.31 (0.69-7.74)
2.27 (1.17-4.40)
0.65 (0.33-1.27)
0.67 (0.34-1.32)
0.28 (0.08-1.02)
1.39 (0.59-3.26)
0.57 (0.21-1.53)
1.05 (0.43-2.59)
1.60 (0.66-3.92)
0.79 (0.33-1.89)
0.42 (0.22-0.83)

(vs Year 1)
0.44 (0.32-0.60)
(vs Year 1)
0.51 (0.39-0.69)
1.20 (0.82-1.76)
1.49 (1.02-2.16)
1.02 (0.74-1.40)
0.86 (0.61-1.21)
1.37 (1.06-1.78)
1.15 (0.89-1.50)
0.99 (0.76-1.30)
1.46 (1.12-1.90)

(vs Year 2)
1.71 (1.01-2.88)
--

Obese vs Normal weight
0.85 (0.37-1.93)
Overweight vs Normal weight
1.21 (0.55-2.69)
Alignment: Valgus vs Normal
0.58 (0.27-1.25)
Alignment: Varus vs Normal
0.70 (0.31-1.59)
K-L: 3/4 vs 2
1.07 (0.59-1.93)
Multi-joint osteoarthritis
0.94 (0.53-1.67)
History of knee injury
1.69 (0.92-3.10)
Use of non-steroidal anti1.06 (0.57-1.94)
inflammatory agents
Use of acetaminophen
1.45 (1.00-2.11)
1.42 (0.58-3.50)
Use of opioids
0.67 (0.40-1.13)
0.61 (0.21-1.75)
Use of complementary/alternative
2.20 (1.69-2.89)
2.90 (1.64-5.12)
medicine
WOMAC Pain #
1.13 (0.98-1.32)
1.23 (0.86-1.75)
SF-12 Physical Component Score #
1.20 (1.02-1.41)
1.32 (0.94-1.84)
#
SF-12 Mental Component Score
1.15 (1.00-1.32)
0.99 (0.75-1.30)
*
Correlates in this table were included in treatment models when analyzing WOMAC Pain as
the outcome.
§
Adjusted for other variables in this table.
#
Odds ratios are per one standard deviation changes in WOMAC Pain or SF-12 subscales.
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Table 4.3. Estimated effects of glucosamine/chondroitin on treating OA among persons with
radiographic knee OA, beta coefficients (95% CI)*
Cumulative exposure to glucosamine/chondroitin#
3
2
1
WOMAC Pain (Minimally important improvement: -4.6 to -1.2)
GEE: Crude §
0.86 (0.10 to 1.61)
0.14 (-0.33 to 0.60)
0 (-0.36 to 0.37)
§
GEE: Full-adjusted
0.81 (0.16 to 1.45)
0.07 (-0.30 to 0.45)
0.20 (-0.04 to 0.44)
MSM with truncated
0.68 (-0.16 to 1.53)
-0.12 (-0.71 to 0.48)
0.28 (-0.08 to 0.65)
weights
WOMAC Stiffness (Minimally important improvement: -1.5 to -0.5)
§
GEE: Crude
0.48 (0.08 to 0.89)
0.09 (-0.17 to 0.34)
0.14 (-0.04 to 0.31)
GEE: Full-adjusted §
0.41 (0.04 to 0.79)
0.13 (-0.08 to 0.34)
0.17 (0.05 to 0.30)
MSM with truncated
0.41 (0 to 0.82)
0.10 (-0.18 to 0.37)
0.25 (0.06 to 0.43)
weights
WOMAC Function (Minimally important improvement: -9.9 to -4.1)
GEE: Crude §
2.56 (0.64 to 4.48)
1.23 (-0.17 to 2.64)
-0.06 (-1.15 to 1.02)
GEE: Full-adjusted §
1.74 (0.03 to 3.46)
0.94 (-0.19 to 2.07)
0.31 (-0.41 to 1.03)
MSM with truncated
1.28 (-1.23 to 3.79)
0.24 (-1.45 to 1.94)
0.66 (-0.50 to 1.82)
weights
Joint space width (Minimally important improvement: 0.2 to 0.5)
GEE: Crude §
-0.35 (-0.58 to -0.12)
-0.25 (-0.45 to -0.06)
-0.12 (-0.23 to -0.01)
§
GEE: Full-adjusted
0.05 (-0.13 to 0.22)
0.04 (-0.08 to 0.15)
-0.03 (-0.09 to 0.03)
MSM with truncated
0.11 (-0.21 to 0.44)
0.14 (-0.07 to 0.35)
-0.03 (-0.16 to 0.10)
weights
Models

*

The reference group includes persons never using glucosamine/chondroitin up to “previous
visit”.
§
Generalized estimating equations (GEE) analyses assumed an unstructured correlation matrix.
The full-adjusted GEE estimates adjusted for baseline characteristics and time-varying
confounders that were measured at the same visit as glucosamine/chondroitin use.
#
Analyses of WOMAC outcomes and JSW were based on 1,625 persons (4,264 person-visits)
and 1,113 persons (2,367 person-visits), respectively.
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Figure 4.1. Flow-chart of identifying study samples.
Glu/Chon: glucosamine/chondroitin; JSN: joint space narrowing.
*
295 persons were further censored at visits from year 2 to year 4 because the JSW measures were missing or invalid due to poor knee
positioning.

86

Figure 4.2. Hypothesized causal relationships between glucosamine/chondroitin treatment, study outcomes and potential time-varying
confounders.
Glu/Chon denotes treatment with glucosamine/chondroitin and the subscript number denotes the follow-up time (year) when the
information was measured.
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